Insulet (PODD) 10-Q 7 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 01, 2014
Document Documentand Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'PODD	'
Entity Registrant Name	'INSULET CORP	'
Entity Central Index Key	'0001145197	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	55,881,647

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current Assets	'	'
Cash and cash equivalents	$175,545	$149,727
Accounts receivable, net	41,797	33,067
Inventories	8,765	9,464
Prepaid expenses and other current assets	5,725	5,940
Total current assets	231,832	198,198
Property and equipment, net	34,159	32,356
Intangible assets, net	15,882	18,040
Goodwill	37,536	37,536
Other assets	5,919	1,825
Total assets	325,328	287,955
Current Liabilities	'	'
Accounts payable	18,610	19,359
Accrued expenses and other current liabilities	24,588	19,478
Deferred revenue	1,255	900
Current portion of capital lease obligations	2,872	2,637
Current portion of long-term debt	23,874	0
Total current liabilities	71,199	42,374
Capital lease obligations	3,893	5,390
Long-term debt	165,870	113,651
Other long-term liabilities	1,521	1,943
Total liabilities	242,483	163,358
Commitments and contingencies (Note 11)	'	'
Temporary Equity, Redeemable convertible debt	4,961	0
Stockholders’ Equity	'	'
Preferred stock, $.001 par value: Authorized: 5,000,000 shares at June 30, 2014 and December 31, 2013 Issued and outstanding: zero shares at June 30, 2014 and December 31, 2013	0	0
Common stock, $.001 par value: Authorized: 100,000,000 shares at June 30, 2014 and December 31, 2013. Issued and outstanding: 55,495,352 and 54,870,424 shares at June 30, 2014 and December 31, 2013, respectively	55	55
Additional paid-in capital	639,609	651,067
Accumulated deficit	-561,780	-526,525
Total stockholders’ equity	77,884	124,597
Total liabilities, redeemable convertible debt and stockholders’ equity	$325,328	$287,955

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]	'	'
Preferred stock, par value (in USD per share)	$0.00	$0.00
Preferred stock, authorized	5,000,000	5,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (in USD per share)	$0.00	$0.00
Common stock, authorized	100,000,000	100,000,000
Common stock, issued	55,495,352	54,870,424
Common stock, outstanding	55,495,352	54,870,424

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income Statement [Abstract]	'	'	'	'
Revenue	$72,013	$60,092	$141,174	$117,448
Cost of revenue	36,248	33,259	72,601	65,460
Gross profit	35,765	26,833	68,573	51,988
Operating expenses:	'	'	'	'
Research and development	6,677	5,174	13,456	9,570
General and administrative	19,512	13,901	33,771	26,995
Sales and marketing	14,856	13,580	28,512	27,451
Total operating expenses	41,045	32,655	75,739	64,016
Operating loss	-5,280	-5,822	-7,166	-12,028
Interest income	29	37	60	64
Interest expense	-3,975	-4,291	-8,464	-8,646
Other expense, net	-890	0	-625	0
Loss on extinguishment of long-term debt	-18,943	-325	-18,943	-325
Interest and other expense, net	-23,779	-4,579	-27,972	-8,907
Loss before income taxes	-29,059	-10,401	-35,138	-20,935
Income tax expense	-52	-118	-117	-249
Net loss	($29,111)	($10,519)	($35,255)	($21,184)
Net loss per share basic and diluted	($0.53)	($0.20)	($0.64)	($0.40)
Weighted-average number of shares used in calculating net loss per share	55,425,949	53,834,707	55,258,419	53,445,715

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities	'	'
Net loss	($35,255)	($21,184)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities	'	'
Depreciation and amortization	6,100	5,763
Non-cash interest and other expense	5,869	5,808
Stock-based compensation expense	8,577	6,844
Loss on extinguishment of debt	18,943	325
Provision for bad debts	1,804	2,568
Changes in operating assets and liabilities:	'	'
Accounts receivable	-10,534	-2,924
Inventories	699	8,888
Deferred revenue	355	-4,545
Prepaid expenses and other assets	-1,006	-2,055
Accounts payable, accrued expenses and other current liabilities	4,361	3,305
Other long-term liabilities	-422	379
Net cash provided by (used in) operating activities	-509	3,172
Cash flows from investing activities	'	'
Purchases of property and equipment	-5,745	-2,695
Net cash used in investing activities	-5,745	-2,695
Cash flows from financing activities	'	'
Principal payments of capital lease obligations	-1,262	0
Proceeds from issuance of long-term debt, net of issuance costs	194,570	0
Repayment of long-term debt	-160,685	-2,000
Proceeds from issuance of common stock, net of offering costs	5,339	97,605
Payment of withholding taxes in connection with vesting of restricted stock units	-5,890	-2,431
Net cash provided by financing activities	32,072	93,174
Net increase in cash and cash equivalents	25,818	93,651
Cash and cash equivalents, beginning of period	149,727	57,293
Cash and cash equivalents, end of period	175,545	150,944
Allocation to equity for conversion feature for the 2% Notes	35,638	0
Common stock issued in exchange for 5.375% Convertible Senior Notes	0	13,000
Purchases of property and equipment under capital lease	$0	$4,284

Nature_of_the_Business

Nature of the Business	6 Months Ended
	Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Nature of the Business	'
	Nature of the Business
	The Company is primarily engaged in the development, manufacturing and sale of its proprietary OmniPod Insulin Management System (the “OmniPod System”), an innovative, discreet and easy-to-use insulin infusion system for people with insulin-dependent diabetes. The OmniPod System is the only commercially-available insulin infusion system of its kind. The OmniPod System features a unique disposable tubeless OmniPod which is worn on the body for approximately three days at a time and the handheld, wireless Personal Diabetes Manager (“PDM”). Conventional insulin pumps require people with insulin-dependent diabetes to learn to use, manage and wear a number of cumbersome components, including up to 42 inches of tubing. In contrast, the OmniPod System features two discreet, easy-to-use devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provides for virtually pain-free automated cannula insertion, communicates wirelessly and integrates a blood glucose meter.
	In June 2011, the Company acquired Neighborhood Holdings, Inc. and its wholly-owned subsidiaries (collectively, “Neighborhood Diabetes”) in order to expand the Company’s full suite diabetes management product offerings and obtain access to a larger number of insulin dependent patients. Through Neighborhood Diabetes, the Company is able to provide customers with blood glucose testing supplies, traditional insulin pumps, pump supplies and pharmaceuticals and has the ability to process claims as either durable medical equipment or through pharmacy benefits.
	The Company began commercial sale of the OmniPod System in the United States in October 2005. The Company has also expanded the availability of the OmniPod System internationally through its partnerships with Ypsomed Distribution AG (“Ypsomed”) and GlaxoSmithKline (“GSK”). In August 2011, the Company received CE Mark approval, and in December 2012, the Company received 510(k) clearance for the new OmniPod System from the FDA. The Company began selling its new OmniPod System in 2013. The new OmniPod System is more than one-third smaller and one-quarter lighter than the original model, while maintaining the same features and operating capabilities.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	Summary of Significant Accounting Policies
	Basis of Presentation
	The unaudited consolidated financial statements in this Quarterly Report on Form 10-Q have been prepared in accordance with generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these unaudited consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Operating results for the three and six month periods ended June 30, 2014 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2014, or for any other subsequent interim period.
	The unaudited consolidated financial statements in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.
	Use of Estimates in Preparation of Financial Statements
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expense during the reporting periods. The most significant estimates used in these financial statements include the valuation of stock-based compensation expense, accounts receivable, inventories, goodwill, deferred revenue, debt instruments, and equity instruments, the lives of property and equipment and intangible assets, as well as warranty and doubtful accounts allowance reserve calculations. Actual results may differ from those estimates.
	Principles of Consolidation
	The unaudited consolidated financial statements in this Quarterly Report on Form 10-Q include the accounts of the Company and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.
	Fair Value Measurements
	The Company adopted the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, Fair Value Measurements and Disclosures (“ASC 820”) related to the fair value measurement of certain of its assets and liabilities. ASC 820 defines fair value as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A single estimate of fair value results from a complex series of judgments about future events and uncertainties and relies heavily on estimates and assumptions. When estimating fair value, depending on the nature and complexity of the assets or liability, the Company may use one or all of the following approaches:
	•	Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.
	•	Cost approach, which is based on the cost to acquire or construct comparable assets less an allowance for functional and/or economic obsolescence.
	•	Income approach, which is based on the present value of the future stream of net cash flows.
	ASC 820 also describes three levels of inputs that may be used to measure the fair value:
	Level 1 — quoted prices in active markets for identical assets or liabilities
	Level 2 — observable inputs other than quoted prices in active markets for identical assets or liabilities
	Level 3 — unobservable inputs in which there is little or no market data available, which require the reporting entity to develop its own assumptions
	The only assets and liabilities subject to fair value measurement standards at June 30, 2014 and December 31, 2013 are cash equivalents, consisting of money market accounts, and long-term debt which are both based on Level 1 inputs and the June 2014 call feature of the modified portion of the 3.75% Notes (as defined below) which is based on Level 3 inputs.
	Certain of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and other liabilities are carried at cost, which approximates their fair value because of the short-term maturity of these financial instruments.
	Accounts Receivable and Allowance for Doubtful Accounts
	Accounts receivable consist of amounts due from third-party payors, patients, third-party distributors, and government agencies. The allowance for doubtful accounts is recorded at the time collection risk is identified. The Company estimates its allowance based on historical experience, assessment of specific risk, discussions with individual customers and various assumptions and estimates that are believed to be reasonable under the circumstances.
	Inventories
	Inventories are held at the lower of cost or market, determined under the first-in, first-out method. Inventory has been recorded at cost as of June 30, 2014 and December 31, 2013. Work in process is calculated based upon a build up in the stage of completion using estimated labor inputs for each stage in production. The Company periodically reviews inventories for potential impairment based on quantities on hand and expectations of future use.
	Property and Equipment
	Property and equipment is stated at cost and depreciated using the straight-line method over the estimated useful life of the respective assets. Leasehold improvements are amortized over their useful life or the life of the lease, whichever is shorter. Assets acquired under capital leases are amortized in accordance with the respective class of owned assets or life of the lease, and the amortization is included with depreciation expense. Maintenance and repair costs are expensed as incurred.
	Intangibles and Other Long-Lived Assets
	The Company’s finite-lived intangible assets are stated at cost less accumulated amortization. The Company assesses its intangible and other long-lived assets for impairment whenever events or changes in circumstances suggest that the carrying value of an asset may not be recoverable. The Company recognizes an impairment loss for intangibles and other long-lived assets if the carrying amount of the asset is not recoverable based on its undiscounted future cash flows. Any such impairment loss is measured as the difference between the carrying amount and the fair value of the asset. The estimation of useful lives and expected cash flows requires the Company to make significant judgments regarding future periods that are subject to some factors outside its control. Changes in these estimates can result in significant revisions to the carrying value of these assets and may result in material charges to the results of operations. The estimated life of the acquired tradename asset is 15 years. The estimated life of the acquired customer relationship asset is 10 years. Intangible assets with determinable estimated lives are amortized over these lives.
	Goodwill
	Goodwill represents the excess of the cost of the acquired Neighborhood Diabetes businesses over the fair value of identifiable net assets acquired. The company follows the provisions of FASB ASC 350-20, Intangibles - Goodwill and Other (“ASC 350-20”). ASC 350-20 requires companies to use the purchase method of accounting for all business combinations initiated after June 30, 2001, and establishes specific criteria for the recognition of intangible assets separately from goodwill. The Company performs an assessment of its goodwill for impairment on at least an annual basis or whenever events or changes in circumstances indicate there might be impairment.
	The Company continues to operate in one segment, which is considered to be the sole reporting unit and therefore, goodwill was tested for impairment at the enterprise level. To test for impairment, the Company has elected to first assess the qualitative factors to determine whether it is more likely than not that the fair value of its sole reporting unit is less than its carrying amount. This qualitative analysis is used as a basis for determining whether it is necessary to perform the two-step goodwill impairment analysis. If the Company determines that it is more likely than not that its fair value is less than its carrying amount, then the two-step goodwill impairment test will be performed. The first step compares the carrying value of the reporting unit to its fair value using a discounted cash flow analysis. If the reporting unit’s carrying value exceeds its fair value, the Company would record an impairment loss to the extent that the carrying value of goodwill exceeds its implied fair value. No goodwill impairment was recorded in the three and six months ended June 30, 2014.
	Warranty
	The Company provides a four-year warranty on its PDMs and may replace any OmniPods that do not function in accordance with product specifications. The Company estimates its warranty reserves at the time the product is shipped based on historical experience and the estimated cost to service the claims. Cost to service the claims reflects the current product cost, which has been decreasing over time. As these estimates are based on historical experience, and the Company continues to introduce new versions of existing products, the Company also considers the anticipated performance of the product over its warranty period in estimating warranty reserves.
	Revenue Recognition
	The Company generates nearly all of its revenue from sales of its OmniPod System and other diabetes related products including blood glucose testing supplies, traditional insulin pumps, pump supplies and pharmaceuticals to customers and third-party distributors who resell the products to patients with diabetes.
	Revenue recognition requires that persuasive evidence of a sales arrangement exists, delivery of goods occurs through transfer of title and risk and rewards of ownership, the selling price is fixed or determinable and collectability is reasonably assured. With respect to these criteria:
	•	The evidence of an arrangement generally consists of a physician order form, a patient information form and, if applicable, third-party insurance approval for sales directly to patients or a purchase order for sales to a third-party distributor.
	•	Transfer of title and risk and rewards of ownership are passed to the patient or third-party distributor upon shipment of the products.
	•	The selling prices for all sales are fixed and agreed with the patient or third-party distributor and, if applicable, the patient’s third-party insurance provider(s), prior to shipment and are based on established list prices or, in the case of certain third-party insurers, contractually agreed upon prices. Provisions for discounts and rebates to customers are established as a reduction to revenue in the same period the related sales are recorded.
	The Company offers a 45-day right of return for its OmniPod System sales to new patients, and defers revenue to reflect estimated sales returns in the same period that the related product sales are recorded. Returns are estimated through a comparison of the Company’s historical return data to their related sales. Historical rates of return are adjusted for known or expected changes in the marketplace when appropriate. When doubt exists about reasonable assuredness of collectability from specific customers, the Company defers revenue from sales of products to those customers until payment is received.
	In June 2011, the Company entered into a development agreement with a U.S. based pharmaceutical company (the “Development Agreement”). Under the Development Agreement, the Company was required to perform design, development, regulatory and other services to support the pharmaceutical company as it works to obtain regulatory approval to use the Company’s drug delivery technology as a delivery method for its pharmaceutical. Over the term of the Development Agreement, the Company has invoiced amounts based upon meeting certain deliverable milestones. Revenue from the Development Agreement was recognized using a proportional performance methodology based on efforts incurred and total payments under the agreement. The impact of any changes in the expected total effort or contract payments was recognized as a change in estimate using the cumulative catch-up method. As of December 31, 2013, the Company met all required deliverables under the Development Agreement.
	The Company deferred revenue of $1.3 million and $0.9 million as of June 30, 2014 and December 31, 2013, respectively. The deferred revenue recorded at June 30, 2014 was mainly comprised of product-related revenue.
	Concentration of Credit Risk
	Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents. The Company maintains the majority of its cash with two accredited financial institutions.
	The Company purchases complete OmniPods from Flextronics International Ltd., its single source supplier. As of June 30, 2014 and December 31, 2013, approximately 29% and 36%, respectively, of the combined balance of accounts payable, accrued expenses, and other current liabilities, related to amounts owed to this vendor.
	Segment Reporting
	Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated on a regular basis by the chief operating decision-maker, or decision-making group, in deciding how to allocate resources to an individual segment and in assessing performance of the segment. The Company’s current product offering consists of diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies and pharmaceuticals. The Company’s current product offering is marketed to a single customer type, people with diabetes. As the Company sells a single product type, management operates the business as a single entity.
	Income Taxes
	The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates that will be in effect in the years in which the differences are expected to reverse. A valuation allowance is required to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company reviews its deferred tax assets for recoverability considering historical profitability, projected future taxable income, and the expected timing of the reversals of existing temporary differences and tax planning strategies. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.
	The Company follows the provisions of FASB ASC 740-10, Income Taxes (“ASC 740-10”) on the accounting for uncertainty in income taxes recognized in its financial statements. ASC 740-10 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In addition, ASC 740-10 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, and disclosure and transition. The Company recognizes estimated interest and penalties for uncertain tax positions in income tax expense. Interest and penalties were immaterial to the consolidated financial statements in the three and six months ended June 30, 2014 and 2013.
	The Company files federal, state and foreign tax returns. These returns are generally open to examination by the relevant tax authorities from three to four years from the date they are filed. The tax filings relating to the Company's federal and state returns are currently open to examination for tax years 2010 through 2012 and 2009 through 2012, respectively. In addition, the Company has generated tax losses since its inception in 2000. These years may be subject to examination if the losses are carried forward and utilized in future years.
	Stock-Based Compensation
	The Company accounts for stock-based compensation under the provisions of FASB ASC 718-10, Compensation — Stock Compensation (“ASC 718-10”), which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Share-based payments that contain performance conditions are recognized when such conditions are probable of being achieved.
	The Company uses the Black-Scholes option pricing model to determine the fair value of options granted. The Company determines the intrinsic value of restricted stock units based on the closing price of its common stock on the date of grant. The Company recognizes the compensation expense of share-based awards on a straight-line basis for awards with only service conditions and on an accelerated method for awards with performance conditions. Compensation expense is recognized over the respective vesting periods of the awards.
	The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the stock price and a number of assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The expected life of the awards is estimated based on the midpoint between the vesting date and the end of the contractual term. The risk-free interest rate assumption is based on observed interest rates appropriate for the terms of the awards. The dividend yield assumption is based on company history and expectation of paying no dividends. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Stock-based compensation expense recognized in the financial statements is based on awards that are ultimately expected to vest. The Company evaluates the assumptions used to value the awards on a quarterly basis and, if factors change and different assumptions are utilized, stock-based compensation expense may differ significantly from what has been recorded in the past. If there are any modifications or cancellations of the underlying unvested securities, the Company may be required to accelerate, increase or cancel any remaining unearned stock-based compensation expense.
	Recent Accounting Pronouncements Not Yet Adopted
	In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers ("ASU 2014-09"). ASU 2014-09 requires that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. Under this guidance, a company may make additional estimates regarding performance conditions and the allocation of variable consideration. The guidance is effective in fiscal years beginning after January 1, 2017, with early adoption permitted. The Company is evaluating the impact of ASU 2014-09, however the adoption of the guidance is not expected to have a material impact on the Company's financial statements.
	In June 2014, the FASB issued ASU No. 2014-12, Compensation - Stock Compensation (Topic 718), Accounting for Share-Based Payments when the terms of an award provide that a performance target could be achieve after the requisite service period ("ASU 2014-12"). ASU 2014-12 clarifies the period over which compensation cost would be recognized in awards with a performance target that affects vesting and that could be achieved after the requisite service period. Compensation cost would be recognized over the required service period, if it is probable that the performance condition will be achieved. The guidance is effective in fiscal years beginning after January 1, 2016, with early adoption permitted. The Company is evaluating the impact of ASU 2014-12, however the adoption of the guidance is not expected to have a material impact on the Company's financial statements.

Fair_Value_Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	Fair Value Measurements
	ASC 820, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 defines fair value as the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs and minimize the use of unobservable inputs. To measure fair value, the Company uses the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable:
	Level 1 — quoted prices in active markets for identical assets or liabilities
	Level 2 — observable inputs other than quoted prices in active markets for identical assets or liabilities
	Level 3 — unobservable inputs in which there is little or no market data available, which require the reporting entity to develop its own assumptions
	Fair value under ASC 820 is principally applied to financial assets which consist of investments in money market funds and the call feature on the modified portion of the 3.75% Notes. The following table provides a summary of financial assets that are measured at fair value on a recurring basis as of June 30, 2014, aggregated by the level in the fair value hierarchy within which those measurements fall (in thousands):
		Fair Value Measurements
		Total			Level 1		Level 2		Level 3
	Assets
	Cash Equivalents - Money Market Funds	$	123,129		$	123,129	$	—	$	—
	Other Asset - Call feature on the modified portion of the 3.75% Notes	$	702		$	—	$	—	$	702
	The following table provides a summary of financial assets that are measured at fair value on a recurring basis as of December 31, 2013, aggregated by the level in the fair value hierarchy within those those measurements fall (in thousands):
		Fair Value Measurements
		Total			Level 1		Level 2		Level 3
	Assets
	Cash Equivalents - Money Market Funds	$	128,308		$	128,308	$	—	$	—
	Other Asset - Call feature on the modified portion of the 3.75% Notes	$	1,351		$	—	$	—	$	1,351
	Cash and Cash Equivalents
	The fair value of cash and cash equivalents is estimated based on the quoted market price of the investments. The carrying amount of the Company's cash equivalents approximates their fair value due to the short-term maturity of these instruments.
	Other Asset
	The Company's financial assets include a call feature on the outstanding principal amount of the modified portion of the 3.75% Notes which was valued at June 30, 2014 and December 31, 2013 using Level 3 inputs. Gains and losses recognized on changes in fair value of the asset are reported in other income (expense). The valuation of this feature was measured at fair value using a trinomial lattice model which incorporates the terms and conditions of the modified portion of the 3.75% Notes and estimates the fair value based on changes in the price of the underlying equity over successive periods of time. This lattice model is considered to be a single-factor model, in that it solely incorporates uncertainty related to the Company’s stock price and values the option to convert the note into common stock using a trinomial structure. The $0.9 million and $0.6 million decrease in the valuation of this feature in the three and six months ended June 30, 2014, respectively, was a result of the repurchase of a portion of the outstanding principal amount of the modified portion of the 3.75% Notes offset by an increase in the valuation per note. The decrease was was recorded as other expense in the three and six months ended June 30, 2014.
	The key assumptions used in the lattice model valuation for the call feature were as follows:
		As of
		June 30,		31-Dec-13
		2014
	Term to Maturity (years)	2.03		2.46
	Bond Inputs:
	Bond Yield	4.91%		8.61%
	Coupon Rate	3.75%		3.75%
	Conversion Price	$26.20		$26.20
	Bond Call Strike Price	$100.00		$100.00
	Stock Inputs:
	Stock Price	$39.67		$37.10
	Risk Free Rate	0.41%		0.56%
	Volatility	35.30%		38.00%
	Dividend Yield	—%		—%
	The estimated yield is based on a trinomial single-factor convertible bond model which takes into account the conversion option and the call option. The risk free interest rate is based on United States Treasury rates with maturity dates approximating the expected term to maturity of the 3.75% Notes. The expected volatility considers the Company’s historical volatility with a lookback period commensurate with years to maturity of the notes and the implied volatility using call option contracts on the Company’s stock. The Company's stock price increased 7% from $37.10 at December 31, 2013 to $39.67 at June 30, 2014.
	Debt
	The estimated fair value of debt is based on the Level 1 quoted market prices for the same or similar issues.
	The carrying amounts and the estimated fair values of financial instruments as of June 30, 2014 and December 31, 2013, are as follows (in thousands):
		30-Jun-14					31-Dec-13
		Carrying			Estimated Fair		Carrying		Estimated Fair
		Value			Value		Value		Value
	Debt	$	189,744		$	266,529	$	113,651	$	211,370
	The carrying value of the 3.75% Notes at June 30, 2014 and December 31, 2013 includes a debt discount of $5.0 million and $30.1 million, respectively, which is being amortized as non-cash interest expense over the term of the 3.75% Notes. The carrying value of the 2% Notes (as defined below) at June 30, 2014 includes a debt discount of $35.4 million which is being amortized as non-cash interest expense over the term of the 2% Notes. The increase in the estimated fair values of these liabilities from December 31, 2013 to June 30, 2014 is largely related to the issuance of the 2% Notes and an increase in the quoted bond prices.

Debt

Debt	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Debt	'
	Debt
	The Company had outstanding convertible debt and related deferred financing costs on its consolidated balance sheet as follows (in thousands):
		As of
		June 30,			31-Dec-13
		2014
	Principal amount of the 3.75% Convertible Senior Notes	$	28,836		$	143,750
	Principal amount of the 2% Convertible Senior Notes	201,250			—
	Unamortized debt discount	(40,342		)	(30,099		)
	Total long-term debt	$	189,744		$	113,651
	Current portion of long-term debt	23,874			—
	Long-term debt	$	165,870		$	113,651
	Deferred financing costs	$	5,638		$	1,414
	Interest expense related to the 5.375% Notes (as defined below), the 3.75% Notes and the 2% Notes was included in interest expense on the consolidated statements of operations as follows (in thousands):
		Three Months Ended June 30,						Six Months Ended June 30,
		2014			2013			2014		2013
	Contractual coupon interest	$	1,273		$	1,460		$	2,621	$	3,009
	Accretion of debt discount	2,258			2,751			4,883		5,511
	Amortization of debt issuance costs	192			149			338		297
	Loss on extinguishment of long-term debt	18,943			325			18,943		325
	Total interest and other expense	$	22,666		$	4,685		$	26,785	$	9,142
	5.375% Convertible Senior Notes
	In June 2008, the Company sold $85 million in principal amount of 5.375% Convertible Senior Notes due June 15, 2013 (the “5.375% Notes”). The interest rate on the notes was 5.375% per annum on the principal amount from June 16, 2008, payable semi-annually in arrears in cash on December 15 and June 15 of each year. The 5.375% Notes were convertible into the Company’s common stock at an initial conversion rate of 46.8467 shares of common stock per $1,000 principal amount of the 5.375% Notes. The 5.375% Notes were convertible for cash up to their principal amount and shares of the Company’s common stock for the remainder of the conversion value in excess of the principal amount.
	In June 2011, in connection with the issuance of $143.8 million in principal amount of 3.75% Convertible Notes due June 15, 2016 (the “3.75% Notes”), the Company repurchased $70 million in principal amount of the 5.375% Notes for $85.1 million, a 21.5% premium on the principal amount. The investors that held the $70 million in principal amount of repurchased 5.375% Notes purchased $59.5 million in principal amount of the 3.75% Notes and retained approximately $13.5 million in principal amount of the remaining 5.375% Notes. These investors’ combined $73.0 million in principal amount of convertible debt ($13.5 million of 5.375% Notes and $59.5 million of 3.75% Notes) was considered to be a modification of a portion of the 5.375% Notes. See “3.75% Convertible Senior Notes” below for additional detail on the modification accounting.
	In May 2013, the Company entered into an Exchange Agreement with a holder of its 5.375% Notes. Under the Exchange Agreement, the Company purchased $13 million in principal amount of the 5.375% Notes in exchange for 620,122 shares of the Company's common stock and a cash payment of $0.3 million, representing the accrued and unpaid interest. In June 2013, the Company repaid the remaining outstanding principal and accrued interest on the 5.375% Notes in accordance with the terms. In addition to a cash payment of $2.1 million, representing principal and accrued and unpaid interest, the Company issued 26,523 shares of its common stock to the holders, representing the conversion value in excess of the principal amount as per the original terms of the 5.375% Notes.
	No cash interest expense was recorded related to the 5.375% Notes in the three and six month periods ended June 30, 2014. Cash interest expense related to the 5.375% Notes was $0.1 million and $0.3 million in the three and six month periods ended June 30, 2013.
	As of June 30, 2014, no amounts remain outstanding related to the 5.375% Notes.
	3.75% Convertible Senior Notes
	In June 2011, the Company sold $143.8 million in principal amount of the 3.75% Notes. The interest rate on the notes is 3.75% per annum, payable semi-annually in arrears in cash on December 15 and June 15 of each year. The 3.75% Notes are convertible into the Company’s common stock at an initial conversion rate of 38.1749 shares of common stock per $1,000 principal amount of the 3.75% Notes, which is equivalent to a conversion price of approximately $26.20 per share.
	In connection with the issuance of the 3.75% Notes, the Company repurchased $70 million in principal amount of the 5.375% Notes for $85.1 million. The investors that held the $70 million in principal amount of repurchased 5.375% Notes purchased $59.5 million in principal amount of the 3.75% Notes and retained approximately $13.5 million in principal amount of the remaining 5.375% Notes. This transaction was treated as a modification of a portion of the 5.375% Notes. The Company accounted for this modification of existing debt separately from the issuance of the remainder of the 3.75% Notes.
	Prior to the transaction, the $70 million in principal amount of repurchased 5.375% Notes had a debt discount of $10.5 million. This amount remained in debt discount related to the $73 million in principal amount of modified debt. The Company recorded additional debt discount of $15.1 million related to the premium payment in connection with the repurchase and $0.2 million related to the increase in the value of the conversion feature. The debt discount of $25.8 million related to the modified portion of the 3.75% Notes is being amortized as non-cash interest expense at the effective rate of 16.5% over the five year term of the modified debt. The Company paid transaction fees of approximately $2.0 million related to the modification, which were recorded as interest expense at the time of the modification.
	Of the $143.8 million in principal amount of 3.75% Notes issued in June 2011, $84.3 million in principal amount was considered to be an issuance of new debt. The Company recorded a debt discount of $26.6 million related to the $84.3 million in principal amount of 3.75% Notes. The debt discount was recorded as additional paid-in capital to reflect the value of its nonconvertible debt borrowing rate of 12.4% per annum. This debt discount is being amortized as non-cash interest expense over the five year term of the 3.75% Notes. The Company incurred deferred financing costs related to this offering of approximately $2.8 million, of which $0.9 million has been reclassified as an offset to the value of the amount allocated to equity. The remainder is recorded as other assets in the consolidated balance sheet and is being amortized as non-cash interest expense over the five year term of the 3.75% Notes.
	In June 2014, in connection with the issuance of $201.3 million in principal amount of 2% Convertible Senior Notes due June 15, 2019 (the “2% Notes”), the Company repurchased approximately $114.9 million in principal amount of the 3.75% Notes for $160.7 million, a premium of $45.8 million over the principal amount. Investors that held approximately $80.0 million of 3.75% Notes purchased approximately $98.2 million in principal amount of the 2% Notes. The repurchase of the 3.75% Notes was treated as an extinguishment of debt since the fair value of the conversion feature changed by more than 10%. The extinguishment of the 3.75% Notes was accounted for separately from the issuance of the 2% Notes.
	The $160.7 million paid to extinguish the debt was allocated to debt and equity based on their respective fair values immediately prior to the transaction. The Company allocated $112.4 million of the payment to the debt and $48.3 million to equity. A loss on extinguishment of debt of $18.9 million was recorded in the three and six months ended June 30, 2014, representing the excess of the $112.4 million allocated to the debt over its carrying value, net of deferred financing costs.
	At June 30, 2014, approximately $28.8 million in principal amount of 3.75% Notes remain outstanding.
	The 3.75% Notes are convertible prior to March 15, 2016 only upon the occurrence of certain circumstances. The 3.75% Notes were convertible at the option of the holder during the quarter ended June 30, 2014 since the last reported sales price per share of the Company's common stock was equal to or greater than 130% of the conversion price for at least 20 of the 30 trading days ended on March 31, 2014. The 3.75% Notes and any unpaid interest are convertible at the Company’s option for cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock.
	The Company was not entitled to redeem the outstanding 3.75% Notes prior to June 20, 2014. Beginning on June 20, 2014, the Company had the right to redeem the 3.75% Notes, at its option, in whole or in part, if the last reported sale price per share of the Company’s common stock was at least 130% of the conversion price then in effect for at least 20 trading days during a period of 30 consecutive trading days. In June 2014, the Company met the redemption requirements and notified holders of its intent to redeem the outstanding $28.8 million in principal amount of 3.75% Notes in July 2014. Prior to the redemption date, holders of $28.5 million in principal amount of 3.75% Notes notified the Company that they exercised their right to convert their outstanding 3.75% Notes. In July 2014, the Company settled this conversion of the 3.75% Notes by providing cash for the principal amount of the outstanding 3.75% Notes converted and 348,535 shares of common stock representing the conversion premium. The Company settled the redemption of the remaining $0.3 million in principal amount in exchange for a cash payment of $0.3 million representing principal and accrued and unpaid interest.
	The Company identified certain features related to a portion of the 3.75% Notes, including the holders’ ability to require the Company to repurchase their notes and the higher interest payments required in an event of default, which are considered embedded derivatives and should be bifurcated and accounted for at fair value. The Company assesses the value of each of these embedded derivatives at each balance sheet date. The Company separately accounted for the call feature related to the possibility that it can redeem the outstanding 3.75% Notes, at the Company's option, beginning June 20, 2014. The Company determined that the fair value of this feature was approximately $0.7 million and $1.4 million at June 30, 2014 and December 31, 2013, respectively. The Company determined that the remaining derivatives had de minimis value at the balance sheet dates.
	Cash interest expense related to the outstanding 3.75% Notes was $1.1 million and $1.4 million in the three month periods ended June 30, 2014 and 2013, respectively, and $2.4 million and $2.7 million in the six month periods ended June 30, 2014 and 2013, respectively. Non-cash interest expense related to the outstanding 3.75% Notes was $2.1 million and $2.9 million in the three month periods ended June 30, 2014 and 2013, respectively, and $4.9 million and $5.5 million in the six month periods ended June 30, 2014 and 2013, respectively.
	As of June 30, 2014, the Company included $23.9 million on its balance sheet in current portion of long-term debt and $5.0 million in temporary equity related to the outstanding 3.75% Notes. The total balance represents the principal to be repaid in cash upon conversion.
	2% Convertible Senior Notes
	In June 2014, the Company sold $201.3 million in principal amount of the 2% Notes. The interest rate on the notes is 2% per annum, payable semi-annually in arrears in cash on December 15 and June 15 of each year. The 2% Notes are convertible into the Company’s common stock at an initial conversion rate of 21.5019 shares of common stock per $1,000 principal amount of the 2% Notes, which is equivalent to a conversion price of approximately $46.51 per share, subject to adjustment under certain circumstances.
	In June 2014, in connection with the issuance of the 2% Notes, the Company repurchased approximately $114.9 million in principal amount of the 3.75% Notes for $160.7 million, a premium of $45.8 million over the principal amount. Investors that held approximately $80.0 million in repurchased 3.75% Notes purchased approximately $98.2 million in principal amount of the 2% Notes. The repurchase of the 3.75% Notes was treated as an extinguishment of debt since the fair value of the conversion feature changed by more than 10%. The extinguishment of the 3.75% Notes was accounted for separately from the issuance of the 2% Notes. See 3.75% Senior Convertible Notes above for additional detail on the extinguishment accounting.
	The Company recorded a debt discount of $35.6 million related to the 2% Notes. The debt discount was recorded as additional paid-in capital to reflect the value of the Company’s nonconvertible debt borrowing rate of 6.2% per annum. This debt discount is being amortized as non-cash interest expense over the five year term of the 2% Notes. The Company incurred deferred financing costs related to this offering of approximately $6.7 million, of which $1.2 million has been reclassified as an offset to the value of the amount allocated to equity. The remainder is recorded as other assets in the consolidated balance sheet and is being amortized as non-cash interest expense over the five year term of the 2% Notes.
	The Company determined that the higher interest and tax payments required in certain circumstances are considered embedded derivatives and should be bifurcated and accounted for at fair value. The Company assesses the value of the embedded derivatives at each balance sheet date. The Company determined that the derivatives had de minimis value at the balance sheet date.
	Cash interest expense related to the 2% Notes was $0.2 million in the three and six month periods ended June 30, 2014, respectively. Non-cash interest expense related to the 2% Notes was $0.3 million in the three and six month periods ended June 30, 2014, respectively.
	As of June 30, 2014, the Company included $165.9 million on its balance sheet in long-term debt related to the 2% Notes.

Capital_Lease_Obligations

Capital Lease Obligations	6 Months Ended
	Jun. 30, 2014
Leases, Capital [Abstract]	'
Capital Lease Obligations	'
	Capital Lease Obligations
	In the year ended December 31, 2013, the Company acquired $9.0 million of manufacturing equipment under capital leases. The $9.0 million obligation under the capital leases is being repaid in equal monthly installments over the 36 month terms of the leases and includes principal and interest payments with an effective interest rate of 17%. In the year ended December 31, 2013, the Company recorded a $2.5 million charge to expense the value of certain equipment as it was no longer expected to be used in its manufacturing process. The remaining underlying assets have been recorded at their fair value of $6.5 million and are included in property and equipment on the Company's balance sheet as of June 30, 2014. The assets acquired under capital leases are being amortized on a straight-line basis over 5 years in accordance with the Company's policy for depreciation of manufacturing equipment. Amortization expense on assets acquired under capital leases is included with depreciation expense. Amortization expense related to these capital leased assets was $0.4 million and $0.7 million in the three and six months ended June 30, 2014. No amortization expense was recorded on the capital leased assets in the three and six months ended June 30, 2013.
	Assets held under capital leases consist of the following (in thousands):
		As of
		June 30,			December 31, 2013
		2014
	Manufacturing equipment	$	6,510		$	6,510
	Less: Accumulated depreciation	(1,233		)	(582		)
	Total	$	5,277		$	5,928
	The aggregate future minimum lease payments related to these capital leases as of June 30, 2014, are as follows (in thousands):
	Year Ending	Minimum Lease
	December 31,	Payments
	2014 (remaining)	$	1,907
	2015	3,815
	2016	2,409
	Total future minimum lease payments	$	8,131
	Interest expense	(1,366		)
	Total capital lease obligations	$	6,765
	The Company recorded $0.3 million and $0.6 million of interest expense on the capital leases in the three and six months ended June 30, 2014, respectively. No interest expense was recorded on capital leases in the three and six months ended June 30, 2013.

Net_Loss_Per_Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2014
Disclosure Potential Common Shares Excluded From Computation Of Diluted Net Loss Per Share [Abstract]	'
Net Loss Per Share	'
	Net Loss Per Share
	Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period, excluding unvested restricted common shares. Diluted net loss per share is computed using the weighted average number of common shares outstanding and, when dilutive, potential common share equivalents from options, restricted stock units and warrants (using the treasury-stock method), and potential common shares from convertible securities (using the if-converted method). Because the Company reported a net loss for the three and six months ended June 30, 2014 and 2013, all potential common shares have been excluded from the computation of the diluted net loss per share for all periods presented, as the effect would have been anti-dilutive. Such potentially dilutive common share equivalents consist of the following:
		Three and Six Months Ended
		June 30,
		2014	2013
	5.375% Convertible Senior Notes	—	702,701
	3.75% Convertible Senior Notes	1,100,811	5,487,642
	2.00% Convertible Senior Notes	4,327,257	—
	Unvested restricted stock units	968,083	1,058,032
	Outstanding options	1,634,584	2,283,054
	Outstanding warrants	—	62,752
	Total dilutive common shares	8,030,735	9,594,181

Accounts_Receivable

Accounts Receivable	6 Months Ended
	Jun. 30, 2014
Receivables [Abstract]	'
Accounts Receivable	'
	Accounts Receivable
	Accounts receivable consist of amounts due from third-party payors, patients, third-party distributors and government agencies. The Company records an allowance for doubtful accounts at the time potential collection risk is identified. The Company estimates its allowance based on historical experience, assessment of specific risk, discussions with individual customers or various assumptions and estimates that are believed to be reasonable under the circumstances. The Company believes the reserve is adequate to mitigate current collection risk.
	As of June 30, 2014 accounts receivable from two customers represented 16% and 15% of gross accounts receivable, respectively. As of December 31, 2013 accounts receivable from two customers represented approximately 12% and 10% of gross accounts receivable, respectively.
	The components of accounts receivable are as follows (in thousands):
		As of
		June 30,			31-Dec-13
		2014
	Trade receivables	$	48,542		$	40,200
	Allowance for doubtful accounts	(6,745		)	(7,133		)
	Total accounts receivable	$	41,797		$	33,067

Inventories

Inventories	6 Months Ended
	Jun. 30, 2014
Disclosure Components Of Inventories [Abstract]	'
Inventories	'
	Inventories
	Inventories consist of the following (in thousands):
		As of
		June 30,		31-Dec-13
		2014
	Raw materials	$	917	$	399
	Work-in-process	856		1,671
	Finished goods	6,992		7,394
	Total inventories	$	8,765	$	9,464

Other_Intangible_Assets

Other Intangible Assets	6 Months Ended
	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Other Intangible Assets	'
	Other Intangible Assets
	Other intangible assets consist of the following (in thousands):
		As of
		June 30, 2014							31-Dec-13
		Cost		Accumulated Amortization			Net Book Value		Cost		Accumulated Amortization			Net Book Value
	Customer relationships	$	30,100	$	(16,443	)	$	13,657	$	30,100	$	(14,378	)	$	15,722
	Tradename	2,800		(575		)	2,225		2,800		(482		)	2,318
	Total intangible assets	$	32,900	$	(17,018	)	$	15,882	$	32,900	(14,860		)	$	18,040
	The Company recorded $32.9 million of other intangible assets in the year ended December 31, 2011 as a result of the acquisition of Neighborhood Diabetes. The Company determined that the estimated useful life of the customer relationships asset is 10 years and is amortizing the asset over that period using an estimated cash flow pattern. The Company determined that the useful life of the Neighborhood Diabetes tradename is 15 years and is amortizing the asset over that period on a straight-line basis. Amortization expense was approximately $1.1 million and $1.3 million for the three months ended June 30, 2014 and 2013, respectively. Amortization expense was approximately $2.2 million and $2.7 million for the six months ended June 30, 2014 and 2013, respectively.
	Amortization expense expected for the next five years and thereafter is as follows (in thousands):
		Amortization Expense
	Year Ending	Customer Relationships		Tradename			Total
	December 31,
	2014 (remaining)	$	1,725	$	94		$	1,819
	2015	3,064		187			3,251
	2016	2,478		187			2,665
	2017	2,003		187			2,190
	2018	1,619		187			1,806
	Thereafter	2,768		1,383			4,151
	Total	$	13,657	$	2,225		$	15,882
	As of June 30, 2014, the weighted average amortization period of the Company’s intangible assets is approximately 8 years.

Product_Warranty_Costs

Product Warranty Costs	6 Months Ended
	Jun. 30, 2014
Disclosure Product Warranty Liability [Abstract]	'
Product Warranty Costs	'
	Product Warranty Costs
	The Company provides a four-year warranty on its PDMs and may replace any OmniPods that do not function in accordance with product specifications. Warranty expense is estimated and recorded in the period that shipment occurs. The expense, or any required adjustment to expense is based on the Company’s historical experience and the estimated cost to service the claims. A reconciliation of the changes in the Company’s product warranty liability is as follows (in thousands):
		Three Months Ended June 30,						Six Months Ended June 30,
		2014			2013			2014			2013
	Balance at the beginning of the period	$	3,100		$	2,249		$	3,090		$	1,992
	Warranty expense	(150		)	785			542			1,661
	Warranty claims settled	(445		)	(633		)	(1,127		)	(1,252		)
	Balance at the end of the period	$	2,505		$	2,401		$	2,505		$	2,401
		As of
		June 30,			December 31,
		2014			2013
	Composition of balance:
	Short-term	$	994		$	1,173
	Long-term	1,511			1,917
		$	2,505		$	3,090

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Commitments and Contingencies
	Operating Leases
	The Company leases its facilities in Massachusetts, New York, Florida, and Singapore. The Company’s leases are accounted for as operating leases. The leases generally provide for a base rent plus real estate taxes and certain operating expenses related to the leases. The leases in Bedford, Massachusetts expire in September 2014. The leases for Bedford contain escalating payments over the life of the lease. During the year ended December 31, 2013, the Company extended the leases related to its Woburn, Massachusetts, Florida, and Singapore locations. Following the extensions, both the Woburn, Massachusetts and Florida leases expire in December 2014 and the Singapore lease expires in July 2015. The lease in New York expires in April 2015. During the year ended December 31, 2013, the Company entered into a new lease agreement for approximately 90,000 square feet of laboratory and office space in Billerica, Massachusetts. The lease term begins in August 2014 and expires in October 2022. During the six months ended June 30, 2014, the Company amended its existing lease for warehouse space in Billerica, Massachusetts. In addition to extending the term, the lease increased the approximate square footage to 18,000. Following the amendment, the lease now expires in September 2019. The execution of these leases did not result in any material impact to the financial statements for the three and six month periods ended June 30, 2014.
	Certain of the Company’s operating lease agreements contain scheduled rent increases, which are being amortized over the terms of the agreements using the straight-line method and are included in other liabilities in the accompanying consolidated balance sheet. The aggregate future minimum lease payments related to these leases as of June 30, 2014, are as follows (in thousands):
	Year Ending	Minimum Lease
	December 31,	Payments
	2014 (remaining)	$	776
	2015	2,096
	2016	2,057
	2017	2,139
	2018	2,144
	Thereafter	8,249
	Total	$	17,461
	Legal Proceedings
	In June 2014, the Company entered into a Settlement and License Agreement (the "Settlement Agreement") with Becton, Dickinson and Company (“BD”) resolving the lawsuit filed by BD against the Company in the United States District Court for the District of New Jersey alleging that the OmniPod System infringes two of its patents. The Settlement Agreement provides for a one-time cash payment by the Company to BD and a cross-license of certain patent claims. The Company has recorded approximately $7 million of expense related to the one-time cash payment and associated legal fees in connection with the lawsuit. The lawsuit was dismissed with prejudice on July 15, 2014.
	In October 2013, the Company received a letter from the Office of the Massachusetts Attorney General contending that prior to September 2012 Neighborhood Diabetes engaged in improper sales practices by automatically refilling certain prescriptions for MassHealth patients. The Company responded to this letter, stating that Neighborhood Diabetes’ refill practices during the period in question were appropriate and consistent with applicable laws. In light of the preliminary nature of this matter, the Company is unable to reasonably assess its ultimate outcome. However, the Company does not believe it has any material financial exposure at June 30, 2014.
	Indemnifications
	In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations.
	In accordance with its bylaws, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Company’s request in such capacity. There have been no claims to date, and the Company has a director and officer insurance policy that enables it to recover a portion of any amounts paid for future claims.
	At June 30, 2014, the Company is subject to an on-going sales and use tax audit by the Massachusetts Department of Revenue related to Neighborhood Diabetes for a period prior to the acquisition. Under the Merger Agreement, the Company has been indemnified by the former stockholders of Neighborhood Diabetes for any liability resulting from or related to any tax attributable to pre-acquisition periods. The Company has recorded a contingent liability in current liabilities and a corresponding indemnification asset in current assets related to the estimated sales tax payable to the state of Massachusetts for the period under audit.

Equity

Equity	6 Months Ended
	Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Equity	'
	Equity
	In January 2013, in a public offering, the Company issued and sold 4,715,000 shares of its common stock at a price of $20.75 per share. In connection with the offering, the Company received total gross proceeds of $97.8 million, or approximately $92.8 million in net proceeds after deducting underwriting discounts and offering expenses.
	In May 2013, the Company entered into an Exchange Agreement with a holder of its 5.375% Notes. Under the Exchange Agreement, the Company issued 620,122 shares of its common stock to the holder in exchange for the extinguishment of $13 million in principal amount of the 5.375% Notes. In June 2013, in connection with the repayment of the remaining $2 million in principal amount of the 5.375% Notes, the Company issued 26,523 shares of its common stock to the holders representing the conversion value in excess of the principal amount as per the conversion terms of the 5.375% Notes.
	In November 2013, the Company issued 47,392 shares of its common stock as a result of the exercise of warrants.
	The Company grants share-based awards to employees in the form of options to purchase the Company’s common stock, the ability to purchase stock at a discounted price under the employee stock purchase plan and restricted stock units. Stock-based compensation expense related to share-based awards recognized in the three month periods ended June 30, 2014 and 2013 was $4.2 million and $3.8 million, respectively, and was calculated based on awards ultimately expected to vest. Stock-based compensation expense related to share-based awards recognized in the six month periods ended June 30, 2014 and 2013 was $8.6 million and $6.8 million, respectively, and was calculated based on awards ultimately expected to vest. At June 30, 2014, the Company had $36.5 million of total unrecognized compensation expense related to stock options and restricted stock units.
	Stock Options
	In May 2007, in conjunction with the Company's initial public offering, the Company adopted its 2007 Stock Option and Incentive Plan (the "2007 Plan"). The 2007 Plan was amended and restated in November 2008 and May 2012 to provide for the issuance of additional shares and to amend certain other provisions. As of June 30, 2014, 2,544,999 shares remain available for future issuance under the 2007 Plan.
	The following summarizes the activity under the Company’s stock option plans:
		Number of		Weighted		Aggregate
		Options (#)		Average		Intrinsic
				Exercise		Value ($)
				Price ($)
						(In thousands)
	Balance, December 31, 2013	1,828,613		$	16.46
	Granted	227,500		42.67
	Exercised	(403,371	)	12.7		$	11,615	(1	)
	Canceled	(18,158	)	23.09
	Balance, June 30, 2014	1,634,584		$	20.97	$	31,509
	Vested, June 30, 2014	923,061		$	15.27	$	22,523	(2	)
	Vested and expected to vest, June 30, 2014 (3)	1,370,909				$	27,826	(2	)
	-1	The aggregate intrinsic value was calculated based on the positive difference between the fair market value of the Company’s common stock as of the date of exercise and the exercise price of the underlying options.
	-2	The aggregate intrinsic value was calculated based on the positive difference between the fair market value of the Company’s common stock as of June 30, 2014 and the exercise price of the underlying options.
	-3	Represents the number of vested options as of June 30, 2014, plus the number of unvested options expected to vest as of June 30, 2014, based on the unvested options outstanding as of June 30, 2014, adjusted for the estimated forfeiture rate of 16%.
	At June 30, 2014 there were 1,634,584 options outstanding with a weighted average exercise price of $20.97 per share and a weighted average remaining contractual life of 7.0 years. At June 30, 2014 there were 923,061 options exercisable with a weighted average exercise price of $15.27 per share and a weighted average remaining contractual life of 5.7 years.
	Employee stock-based compensation expense related to stock options in each of the three month periods ended June 30, 2014 and 2013 was $1.3 million and was based on awards ultimately expected to vest. Employee stock-based compensation expense related to stock options in the six month periods ended June 30, 2014 and 2013 was $2.9 million and $2.5 million, respectively, and was based on awards ultimately expected to vest. At June 30, 2014, the Company had $10.7 million of total unrecognized compensation expense related to stock options that will be recognized over a weighted average period of 1.3 years.
	Employee Stock Purchase Plan
	As of June 30, 2014 and 2013 the Company had 6,898 and 6,390 shares contingently issued under the employee stock purchase plan (“ESPP”), respectively. In the three and six months ended June 30, 2014 and 2013, the Company recorded no significant stock-based compensation charges related to the ESPP.
	Restricted Stock Units
	In the six months ended June 30, 2014, the Company awarded 321,375 restricted stock units to certain employees and directors, which include 34,500 restricted stock units subject to the achievement of performance conditions (performance-based restricted stock units). The restricted stock units were granted under the 2007 Plan and vest annually over three to four years from the grant date. For performance-based restricted stock units, if the performance conditions are achieved, these restricted stock units will then be subject to service-based vesting requirements over a three year period. The number of performance-based restricted stock units granted during the six months ended June 30, 2014 that are expected to vest may vary based on the Company’s quarterly evaluation of the probability of the performance criteria being achieved. The Company expects that 34,500 performance-based restricted stock units granted during the first six months of 2014 will be earned based on the Company’s evaluation of the performance criteria at June 30, 2014. The restricted stock units granted have a weighted average fair value of $45.51 per share based on the closing price of the Company’s common stock on the date of grant. The restricted stock units granted during the six months ended June 30, 2014 were valued at approximately $14.6 million on their grant date, and the Company is recognizing the compensation expense over the vesting period. Approximately $2.9 million and $2.5 million of stock-based compensation expense related to the vesting of restricted stock units was recognized in the three months ended June 30, 2014 and 2013, respectively. Approximately $5.7 million and $4.3 million of stock-based compensation expense related to the vesting of restricted stock units was recognized in the six months ended June 30, 2014 and 2013, respectively. Approximately $25.8 million of the fair value of the restricted stock units remained unrecognized as of June 30, 2014 and will be recognized over a weighted average period of 1.5 years. Under the terms of the awards, the Company will issue shares of common stock on each of the vesting dates.
	The following table summarizes the status of the Company’s restricted stock units:
		Number of		Weighted
		Shares (#)		Average
				Fair Value ($)
	Balance, December 31, 2013	1,011,893		$	22.11
	Granted	321,375		45.51
	Vested	(342,990	)	21.1
	Forfeited	(22,195	)	21.46
	Balance, June 30, 2014	968,083		$	30.25

Income_Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	The Company accounts for income taxes under ASC 740-10. Deferred income tax assets and liabilities are determined based upon differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is required to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. At June 30, 2014 and December 31, 2013, the Company provided a valuation allowance for the full amount of its net deferred tax asset because realization of any future tax benefit was not sufficiently assured.
	Income tax expense consists of the following (in thousands):
		Three Months Ended June 30,				Six Months Ended June 30,
		2014		2013		2014		2013
	Current	$	22	$	88	$	53	$	191
	Deferred	30		30		64		58
	Total	$	52	$	118	$	117	$	249
	In the three and six months ended June 30, 2014 and 2013, the current portion of income tax expense primarily relates to state, local and foreign taxes, and the deferred portion primarily relates to federal and state tax amounts.
	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes as well as federal and state net operating losses and tax credit carryforwards.
	In the future, the Company will generate additional deferred tax assets and liabilities related to its amortization of acquired intangible assets for tax purposes because these long-lived intangible assets are not amortized for financial reporting purposes. The tax amortization in future years will give rise to a temporary difference and a tax liability, which will only reverse at the time of ultimate sale or further impairment of the underlying intangible assets. Due to the uncertain timing of this reversal, the temporary difference cannot be considered as a source of future taxable income for purposes of determining a valuation allowance; therefore, the tax liability cannot be used to offset the deferred tax asset related to the net operating loss carryforward for tax purposes that will be generated by the same amortization.
	The Company had no unrecognized tax benefits at June 30, 2014.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2014
Basis of Presentation	'
	Basis of Presentation
	The unaudited consolidated financial statements in this Quarterly Report on Form 10-Q have been prepared in accordance with generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these unaudited consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Operating results for the three and six month periods ended June 30, 2014 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2014, or for any other subsequent interim period.
	The unaudited consolidated financial statements in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.
Use of Estimates in Preparation of Financial Statements	'
	Use of Estimates in Preparation of Financial Statements
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expense during the reporting periods. The most significant estimates used in these financial statements include the valuation of stock-based compensation expense, accounts receivable, inventories, goodwill, deferred revenue, debt instruments, and equity instruments, the lives of property and equipment and intangible assets, as well as warranty and doubtful accounts allowance reserve calculations. Actual results may differ from those estimates.
Principles of Consolidation	'
	Principles of Consolidation
	The unaudited consolidated financial statements in this Quarterly Report on Form 10-Q include the accounts of the Company and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.
Fair Value Measurements	'
	Fair Value Measurements
	The Company adopted the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, Fair Value Measurements and Disclosures (“ASC 820”) related to the fair value measurement of certain of its assets and liabilities. ASC 820 defines fair value as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A single estimate of fair value results from a complex series of judgments about future events and uncertainties and relies heavily on estimates and assumptions. When estimating fair value, depending on the nature and complexity of the assets or liability, the Company may use one or all of the following approaches:
	•	Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.
	•	Cost approach, which is based on the cost to acquire or construct comparable assets less an allowance for functional and/or economic obsolescence.
	•	Income approach, which is based on the present value of the future stream of net cash flows.
	ASC 820 also describes three levels of inputs that may be used to measure the fair value:
	Level 1 — quoted prices in active markets for identical assets or liabilities
	Level 2 — observable inputs other than quoted prices in active markets for identical assets or liabilities
	Level 3 — unobservable inputs in which there is little or no market data available, which require the reporting entity to develop its own assumptions
	The only assets and liabilities subject to fair value measurement standards at June 30, 2014 and December 31, 2013 are cash equivalents, consisting of money market accounts, and long-term debt which are both based on Level 1 inputs and the June 2014 call feature of the modified portion of the 3.75% Notes (as defined below) which is based on Level 3 inputs.
	Certain of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and other liabilities are carried at cost, which approximates their fair value because of the short-term maturity of these financial instruments.
Accounts Receivable and Allowance for Doubtful Accounts	'
	Accounts Receivable and Allowance for Doubtful Accounts
	Accounts receivable consist of amounts due from third-party payors, patients, third-party distributors, and government agencies. The allowance for doubtful accounts is recorded at the time collection risk is identified. The Company estimates its allowance based on historical experience, assessment of specific risk, discussions with individual customers and various assumptions and estimates that are believed to be reasonable under the circumstances.
Inventories	'
	Inventories
	Inventories are held at the lower of cost or market, determined under the first-in, first-out method. Inventory has been recorded at cost as of June 30, 2014 and December 31, 2013. Work in process is calculated based upon a build up in the stage of completion using estimated labor inputs for each stage in production. The Company periodically reviews inventories for potential impairment based on quantities on hand and expectations of future use.
Property and Equipment	'
	Property and Equipment
	Property and equipment is stated at cost and depreciated using the straight-line method over the estimated useful life of the respective assets. Leasehold improvements are amortized over their useful life or the life of the lease, whichever is shorter. Assets acquired under capital leases are amortized in accordance with the respective class of owned assets or life of the lease, and the amortization is included with depreciation expense. Maintenance and repair costs are expensed as incurred.
Intangibles and Other Long-Lived Assets	'
	Intangibles and Other Long-Lived Assets
	The Company’s finite-lived intangible assets are stated at cost less accumulated amortization. The Company assesses its intangible and other long-lived assets for impairment whenever events or changes in circumstances suggest that the carrying value of an asset may not be recoverable. The Company recognizes an impairment loss for intangibles and other long-lived assets if the carrying amount of the asset is not recoverable based on its undiscounted future cash flows. Any such impairment loss is measured as the difference between the carrying amount and the fair value of the asset. The estimation of useful lives and expected cash flows requires the Company to make significant judgments regarding future periods that are subject to some factors outside its control. Changes in these estimates can result in significant revisions to the carrying value of these assets and may result in material charges to the results of operations. The estimated life of the acquired tradename asset is 15 years. The estimated life of the acquired customer relationship asset is 10 years. Intangible assets with determinable estimated lives are amortized over these lives.
Goodwill	'
	Goodwill
	Goodwill represents the excess of the cost of the acquired Neighborhood Diabetes businesses over the fair value of identifiable net assets acquired. The company follows the provisions of FASB ASC 350-20, Intangibles - Goodwill and Other (“ASC 350-20”). ASC 350-20 requires companies to use the purchase method of accounting for all business combinations initiated after June 30, 2001, and establishes specific criteria for the recognition of intangible assets separately from goodwill. The Company performs an assessment of its goodwill for impairment on at least an annual basis or whenever events or changes in circumstances indicate there might be impairment.
	The Company continues to operate in one segment, which is considered to be the sole reporting unit and therefore, goodwill was tested for impairment at the enterprise level. To test for impairment, the Company has elected to first assess the qualitative factors to determine whether it is more likely than not that the fair value of its sole reporting unit is less than its carrying amount. This qualitative analysis is used as a basis for determining whether it is necessary to perform the two-step goodwill impairment analysis. If the Company determines that it is more likely than not that its fair value is less than its carrying amount, then the two-step goodwill impairment test will be performed. The first step compares the carrying value of the reporting unit to its fair value using a discounted cash flow analysis. If the reporting unit’s carrying value exceeds its fair value, the Company would record an impairment loss to the extent that the carrying value of goodwill exceeds its implied fair value. No goodwill impairment was recorded in the three and six months ended June 30, 2014.
Warranty	'
	Warranty
	The Company provides a four-year warranty on its PDMs and may replace any OmniPods that do not function in accordance with product specifications. The Company estimates its warranty reserves at the time the product is shipped based on historical experience and the estimated cost to service the claims. Cost to service the claims reflects the current product cost, which has been decreasing over time. As these estimates are based on historical experience, and the Company continues to introduce new versions of existing products, the Company also considers the anticipated performance of the product over its warranty period in estimating warranty reserves.
Revenue Recognition	'
	Revenue Recognition
	The Company generates nearly all of its revenue from sales of its OmniPod System and other diabetes related products including blood glucose testing supplies, traditional insulin pumps, pump supplies and pharmaceuticals to customers and third-party distributors who resell the products to patients with diabetes.
	Revenue recognition requires that persuasive evidence of a sales arrangement exists, delivery of goods occurs through transfer of title and risk and rewards of ownership, the selling price is fixed or determinable and collectability is reasonably assured. With respect to these criteria:
	•	The evidence of an arrangement generally consists of a physician order form, a patient information form and, if applicable, third-party insurance approval for sales directly to patients or a purchase order for sales to a third-party distributor.
	•	Transfer of title and risk and rewards of ownership are passed to the patient or third-party distributor upon shipment of the products.
	•	The selling prices for all sales are fixed and agreed with the patient or third-party distributor and, if applicable, the patient’s third-party insurance provider(s), prior to shipment and are based on established list prices or, in the case of certain third-party insurers, contractually agreed upon prices. Provisions for discounts and rebates to customers are established as a reduction to revenue in the same period the related sales are recorded.
	The Company offers a 45-day right of return for its OmniPod System sales to new patients, and defers revenue to reflect estimated sales returns in the same period that the related product sales are recorded. Returns are estimated through a comparison of the Company’s historical return data to their related sales. Historical rates of return are adjusted for known or expected changes in the marketplace when appropriate. When doubt exists about reasonable assuredness of collectability from specific customers, the Company defers revenue from sales of products to those customers until payment is received.
	In June 2011, the Company entered into a development agreement with a U.S. based pharmaceutical company (the “Development Agreement”). Under the Development Agreement, the Company was required to perform design, development, regulatory and other services to support the pharmaceutical company as it works to obtain regulatory approval to use the Company’s drug delivery technology as a delivery method for its pharmaceutical. Over the term of the Development Agreement, the Company has invoiced amounts based upon meeting certain deliverable milestones. Revenue from the Development Agreement was recognized using a proportional performance methodology based on efforts incurred and total payments under the agreement. The impact of any changes in the expected total effort or contract payments was recognized as a change in estimate using the cumulative catch-up method. As of December 31, 2013, the Company met all required deliverables under the Development Agreement.
	The Company deferred revenue of $1.3 million and $0.9 million as of June 30, 2014 and December 31, 2013, respectively. The deferred revenue recorded at June 30, 2014 was mainly comprised of product-related revenue.
Concentration of Credit Risk	'
	Concentration of Credit Risk
	Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents. The Company maintains the majority of its cash with two accredited financial institutions.
	The Company purchases complete OmniPods from Flextronics International Ltd., its single source supplier. As of June 30, 2014 and December 31, 2013, approximately 29% and 36%, respectively, of the combined balance of accounts payable, accrued expenses, and other current liabilities, related to amounts owed to this vendor.
Segment Reporting	'
	Segment Reporting
	Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated on a regular basis by the chief operating decision-maker, or decision-making group, in deciding how to allocate resources to an individual segment and in assessing performance of the segment. The Company’s current product offering consists of diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies and pharmaceuticals. The Company’s current product offering is marketed to a single customer type, people with diabetes. As the Company sells a single product type, management operates the business as a single entity.
Income Taxes	'
	Income Taxes
	The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates that will be in effect in the years in which the differences are expected to reverse. A valuation allowance is required to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company reviews its deferred tax assets for recoverability considering historical profitability, projected future taxable income, and the expected timing of the reversals of existing temporary differences and tax planning strategies. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.
	The Company follows the provisions of FASB ASC 740-10, Income Taxes (“ASC 740-10”) on the accounting for uncertainty in income taxes recognized in its financial statements. ASC 740-10 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In addition, ASC 740-10 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, and disclosure and transition. The Company recognizes estimated interest and penalties for uncertain tax positions in income tax expense. Interest and penalties were immaterial to the consolidated financial statements in the three and six months ended June 30, 2014 and 2013.
	The Company files federal, state and foreign tax returns. These returns are generally open to examination by the relevant tax authorities from three to four years from the date they are filed. The tax filings relating to the Company's federal and state returns are currently open to examination for tax years 2010 through 2012 and 2009 through 2012, respectively. In addition, the Company has generated tax losses since its inception in 2000. These years may be subject to examination if the losses are carried forward and utilized in future years.
Stock Based Compensation	'
	Stock-Based Compensation
	The Company accounts for stock-based compensation under the provisions of FASB ASC 718-10, Compensation — Stock Compensation (“ASC 718-10”), which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Share-based payments that contain performance conditions are recognized when such conditions are probable of being achieved.
	The Company uses the Black-Scholes option pricing model to determine the fair value of options granted. The Company determines the intrinsic value of restricted stock units based on the closing price of its common stock on the date of grant. The Company recognizes the compensation expense of share-based awards on a straight-line basis for awards with only service conditions and on an accelerated method for awards with performance conditions. Compensation expense is recognized over the respective vesting periods of the awards.
	The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the stock price and a number of assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The expected life of the awards is estimated based on the midpoint between the vesting date and the end of the contractual term. The risk-free interest rate assumption is based on observed interest rates appropriate for the terms of the awards. The dividend yield assumption is based on company history and expectation of paying no dividends. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Stock-based compensation expense recognized in the financial statements is based on awards that are ultimately expected to vest. The Company evaluates the assumptions used to value the awards on a quarterly basis and, if factors change and different assumptions are utilized, stock-based compensation expense may differ significantly from what has been recorded in the past. If there are any modifications or cancellations of the underlying unvested securities, the Company may be required to accelerate, increase or cancel any remaining unearned stock-based compensation expense.
Recent Accounting Pronouncements Not Yet Adopted	'
	Recent Accounting Pronouncements Not Yet Adopted
	In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers ("ASU 2014-09"). ASU 2014-09 requires that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. Under this guidance, a company may make additional estimates regarding performance conditions and the allocation of variable consideration. The guidance is effective in fiscal years beginning after January 1, 2017, with early adoption permitted. The Company is evaluating the impact of ASU 2014-09, however the adoption of the guidance is not expected to have a material impact on the Company's financial statements.
	In June 2014, the FASB issued ASU No. 2014-12, Compensation - Stock Compensation (Topic 718), Accounting for Share-Based Payments when the terms of an award provide that a performance target could be achieve after the requisite service period ("ASU 2014-12"). ASU 2014-12 clarifies the period over which compensation cost would be recognized in awards with a performance target that affects vesting and that could be achieved after the requisite service period. Compensation cost would be recognized over the required service period, if it is probable that the performance condition will be achieved. The guidance is effective in fiscal years beginning after January 1, 2016, with early adoption permitted. The Company is evaluating the impact of ASU 2014-12, however the adoption of the guidance is not expected to have a material impact on the Company's financial statements.

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value, Assets Measured on Recurring and Nonrecurring Basis	'
	The following table provides a summary of financial assets that are measured at fair value on a recurring basis as of June 30, 2014, aggregated by the level in the fair value hierarchy within which those measurements fall (in thousands):
		Fair Value Measurements
		Total			Level 1		Level 2		Level 3
	Assets
	Cash Equivalents - Money Market Funds	$	123,129		$	123,129	$	—	$	—
	Other Asset - Call feature on the modified portion of the 3.75% Notes	$	702		$	—	$	—	$	702
	The following table provides a summary of financial assets that are measured at fair value on a recurring basis as of December 31, 2013, aggregated by the level in the fair value hierarchy within those those measurements fall (in thousands):
		Fair Value Measurements
		Total			Level 1		Level 2		Level 3
	Assets
	Cash Equivalents - Money Market Funds	$	128,308		$	128,308	$	—	$	—
	Other Asset - Call feature on the modified portion of the 3.75% Notes	$	1,351		$	—	$	—	$	1,351
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	'
	The key assumptions used in the lattice model valuation for the call feature were as follows:
		As of
		June 30,		31-Dec-13
		2014
	Term to Maturity (years)	2.03		2.46
	Bond Inputs:
	Bond Yield	4.91%		8.61%
	Coupon Rate	3.75%		3.75%
	Conversion Price	$26.20		$26.20
	Bond Call Strike Price	$100.00		$100.00
	Stock Inputs:
	Stock Price	$39.67		$37.10
	Risk Free Rate	0.41%		0.56%
	Volatility	35.30%		38.00%
	Dividend Yield	—%		—%
Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis	'
	The carrying amounts and the estimated fair values of financial instruments as of June 30, 2014 and December 31, 2013, are as follows (in thousands):
		30-Jun-14					31-Dec-13
		Carrying			Estimated Fair		Carrying		Estimated Fair
		Value			Value		Value		Value
	Debt	$	189,744		$	266,529	$	113,651	$	211,370

Debt_Tables

Debt (Tables)	6 Months Ended
	Jun. 30, 2014
Outstanding Convertible Debt and Related Deferred Financing Costs	'
	The Company had outstanding convertible debt and related deferred financing costs on its consolidated balance sheet as follows (in thousands):
		As of
		June 30,			31-Dec-13
		2014
	Principal amount of the 3.75% Convertible Senior Notes	$	28,836		$	143,750
	Principal amount of the 2% Convertible Senior Notes	201,250			—
	Unamortized debt discount	(40,342		)	(30,099		)
	Total long-term debt	$	189,744		$	113,651
	Current portion of long-term debt	23,874			—
	Long-term debt	$	165,870		$	113,651
	Deferred financing costs	$	5,638		$	1,414
Interest and Other Expense	'
	Interest expense related to the 5.375% Notes (as defined below), the 3.75% Notes and the 2% Notes was included in interest expense on the consolidated statements of operations as follows (in thousands):
		Three Months Ended June 30,						Six Months Ended June 30,
		2014			2013			2014		2013
	Contractual coupon interest	$	1,273		$	1,460		$	2,621	$	3,009
	Accretion of debt discount	2,258			2,751			4,883		5,511
	Amortization of debt issuance costs	192			149			338		297
	Loss on extinguishment of long-term debt	18,943			325			18,943		325
	Total interest and other expense	$	22,666		$	4,685		$	26,785	$	9,142

Capital_Lease_Obligations_Tabl

Capital Lease Obligations (Tables)	6 Months Ended
	Jun. 30, 2014
Leases, Capital [Abstract]	'
Schedule of Capital Leased Assets	'
	Assets held under capital leases consist of the following (in thousands):
		As of
		June 30,			December 31, 2013
		2014
	Manufacturing equipment	$	6,510		$	6,510
	Less: Accumulated depreciation	(1,233		)	(582		)
	Total	$	5,277		$	5,928
Schedule of Future Minimum Lease Payments for Capital Leases	'
	The aggregate future minimum lease payments related to these capital leases as of June 30, 2014, are as follows (in thousands):
	Year Ending	Minimum Lease
	December 31,	Payments
	2014 (remaining)	$	1,907
	2015	3,815
	2016	2,409
	Total future minimum lease payments	$	8,131
	Interest expense	(1,366		)
	Total capital lease obligations	$	6,765

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2014
Disclosure Potential Common Shares Excluded From Computation Of Diluted Net Loss Per Share [Abstract]	'
Potential Common Shares Excluded from Computation of Diluted Net Loss per Share	'
	Such potentially dilutive common share equivalents consist of the following:
		Three and Six Months Ended
		June 30,
		2014	2013
	5.375% Convertible Senior Notes	—	702,701
	3.75% Convertible Senior Notes	1,100,811	5,487,642
	2.00% Convertible Senior Notes	4,327,257	—
	Unvested restricted stock units	968,083	1,058,032
	Outstanding options	1,634,584	2,283,054
	Outstanding warrants	—	62,752
	Total dilutive common shares	8,030,735	9,594,181

Accounts_Receivable_Tables

Accounts Receivable (Tables)	6 Months Ended
	Jun. 30, 2014
Receivables [Abstract]	'
Components of Accounts Receivable	'
	The components of accounts receivable are as follows (in thousands):
		As of
		June 30,			31-Dec-13
		2014
	Trade receivables	$	48,542		$	40,200
	Allowance for doubtful accounts	(6,745		)	(7,133		)
	Total accounts receivable	$	41,797		$	33,067

Inventories_Tables

Inventories (Tables)	6 Months Ended
	Jun. 30, 2014
Components of Inventories	'
	Inventories consist of the following (in thousands):
		As of
		June 30,		31-Dec-13
		2014
	Raw materials	$	917	$	399
	Work-in-process	856		1,671
	Finished goods	6,992		7,394
	Total inventories	$	8,765	$	9,464

Other_Intangible_Assets_Tables

Other Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Components of Other Intangible Assets	'
	Other intangible assets consist of the following (in thousands):
		As of
		June 30, 2014							31-Dec-13
		Cost		Accumulated Amortization			Net Book Value		Cost		Accumulated Amortization			Net Book Value
	Customer relationships	$	30,100	$	(16,443	)	$	13,657	$	30,100	$	(14,378	)	$	15,722
	Tradename	2,800		(575		)	2,225		2,800		(482		)	2,318
	Total intangible assets	$	32,900	$	(17,018	)	$	15,882	$	32,900	(14,860		)	$	18,040
Amortization Expense Expected for Next Five Years	'
	Amortization expense expected for the next five years and thereafter is as follows (in thousands):
		Amortization Expense
	Year Ending	Customer Relationships		Tradename			Total
	December 31,
	2014 (remaining)	$	1,725	$	94		$	1,819
	2015	3,064		187			3,251
	2016	2,478		187			2,665
	2017	2,003		187			2,190
	2018	1,619		187			1,806
	Thereafter	2,768		1,383			4,151
	Total	$	13,657	$	2,225		$	15,882

Product_Warranty_Costs_Tables

Product Warranty Costs (Tables)	6 Months Ended
	Jun. 30, 2014
Reconciliation of Changes in Product Warranty Liability	'
	A reconciliation of the changes in the Company’s product warranty liability is as follows (in thousands):
		Three Months Ended June 30,						Six Months Ended June 30,
		2014			2013			2014			2013
	Balance at the beginning of the period	$	3,100		$	2,249		$	3,090		$	1,992
	Warranty expense	(150		)	785			542			1,661
	Warranty claims settled	(445		)	(633		)	(1,127		)	(1,252		)
	Balance at the end of the period	$	2,505		$	2,401		$	2,505		$	2,401
		As of
		June 30,			December 31,
		2014			2013
	Composition of balance:
	Short-term	$	994		$	1,173
	Long-term	1,511			1,917
		$	2,505		$	3,090

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Aggregate Future Minimum Lease Payments	'
	The aggregate future minimum lease payments related to these leases as of June 30, 2014, are as follows (in thousands):
	Year Ending	Minimum Lease
	December 31,	Payments
	2014 (remaining)	$	776
	2015	2,096
	2016	2,057
	2017	2,139
	2018	2,144
	Thereafter	8,249
	Total	$	17,461

Equity_Tables

Equity (Tables)	6 Months Ended
	Jun. 30, 2014
Stock Option Activity	'
	The following summarizes the activity under the Company’s stock option plans:
		Number of		Weighted		Aggregate
		Options (#)		Average		Intrinsic
				Exercise		Value ($)
				Price ($)
						(In thousands)
	Balance, December 31, 2013	1,828,613		$	16.46
	Granted	227,500		42.67
	Exercised	(403,371	)	12.7		$	11,615	(1	)
	Canceled	(18,158	)	23.09
	Balance, June 30, 2014	1,634,584		$	20.97	$	31,509
	Vested, June 30, 2014	923,061		$	15.27	$	22,523	(2	)
	Vested and expected to vest, June 30, 2014 (3)	1,370,909				$	27,826	(2	)
	-1	The aggregate intrinsic value was calculated based on the positive difference between the fair market value of the Company’s common stock as of the date of exercise and the exercise price of the underlying options.
	-2	The aggregate intrinsic value was calculated based on the positive difference between the fair market value of the Company’s common stock as of June 30, 2014 and the exercise price of the underlying options.
	-3	Represents the number of vested options as of June 30, 2014, plus the number of unvested options expected to vest as of June 30, 2014, based on the unvested options outstanding as of June 30, 2014, adjusted for the estimated forfeiture rate of 16%.
Summary of Restricted Stock Units	'
	The following table summarizes the status of the Company’s restricted stock units:
		Number of		Weighted
		Shares (#)		Average
				Fair Value ($)
	Balance, December 31, 2013	1,011,893		$	22.11
	Granted	321,375		45.51
	Vested	(342,990	)	21.1
	Forfeited	(22,195	)	21.46
	Balance, June 30, 2014	968,083		$	30.25

Income_Taxes_Tables

Income Taxes (Tables)	6 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Tax expense	'
	Income tax expense consists of the following (in thousands):
		Three Months Ended June 30,				Six Months Ended June 30,
		2014		2013		2014		2013
	Current	$	22	$	88	$	53	$	191
	Deferred	30		30		64		58
	Total	$	52	$	118	$	117	$	249

Nature_of_Business_Details

Nature of Business (Details)	Jun. 30, 2014
	in
Nature of Business [Line Items]	'
Number of Inches of Tubing in conventional insulin pump	42

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Detail) (USD $)

3 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

12 Months Ended

6 Months Ended

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2011

Jun. 30, 2014

Dec. 31, 2013

Dec. 31, 2011

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

location

segment

customer

Maximum

Minimum

Tradename [Member]

Tradename [Member]

Tradename [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Neighborhood Diabetes

Neighborhood Diabetes

customer

location

Tradename [Member]

Customer Relationships [Member]

customer

Maximum

Maximum

Significant Accounting Policies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Goodwill impairment loss

$0

$0

'

'

'

'

'

'

'

'

'

'

'

Number of Open Tax Years

'

'

'

'4 years

'3 years

'

'

'

'

'

'

'

'

Estimated useful life

'

'

'

'

'

'15 years

'

'

'10 years

'

'

'15 years

'10 years

Intangible assets

15,882,000

15,882,000

18,040,000

'

'

'

2,225,000

2,318,000

'

13,657,000

15,722,000

'

'

Product warranty term for PDMs

'

'4 years

'

'

'

'

'

'

'

'

'

'

'

Right of return period for Starter Kits sales

'

'45 days

'

'

'

'

'

'

'

'

'

'

'

Deferred revenue

$1,300,000

$1,300,000

$900,000

'

'

'

'

'

'

'

'

'

'

Number of accredited financial institutions which the Company maintains the majority of its cash

2

2

'

'

'

'

'

'

'

'

'

'

'

Number of Single Source Suppliers

1

1

1

'

'

'

'

'

'

'

'

'

'

Number of operating segment

'

1

'

'

'

'

'

'

'

'

'

'

'

Concentration Risk, Percentage

'

29.00%

36.00%

'

'

'

'

'

'

'

'

'

'

Fair_Value_Measurements_Schedu

Fair Value Measurements - Schedule of Assets Measured on a Recurring and Nonrecurring Basis (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash Equivalents - Money Market Funds	$123,129	$128,308
Other Asset - Call feature on the modified portion of the 3.75% Notes	702	1,351
Level 1	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash Equivalents - Money Market Funds	123,129	128,308
Other Asset - Call feature on the modified portion of the 3.75% Notes	0	0
Level 2	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash Equivalents - Money Market Funds	0	0
Other Asset - Call feature on the modified portion of the 3.75% Notes	0	0
Level 3	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash Equivalents - Money Market Funds	0	0
Other Asset - Call feature on the modified portion of the 3.75% Notes	$702	$1,351

Fair_Value_Measurements_Schedu1

Fair Value Measurements - Schedule of Liabilities Measure on Recurring and Nonrecurring Basis (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Carrying Value	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Debt	$189,744	$113,651
Estimated Fair Value	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Debt	$266,529	$211,370

Fair_Value_Measurements_Fair_V

Fair Value Measurements - Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques (Details) (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'	'
Term to Maturity (years)	'2 years 0 months 12 days	'2 years 5 months 15 days
Bond Yield	4.91%	8.61%
Coupon Rate	3.75%	3.75%
Conversion Price	$26.20	$26.20
Bond Call Strike Price	$100	$100
Stock Price	$39.67	$37.10
Risk Free Rate	0.41%	0.56%
Volatility	35.30%	38.00%
Dividend Yield	0.00%	0.00%

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Details) (USD $)	3 Months Ended	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Debt Discount, Unamortized	$4,961,000	$4,961,000	$0
Stock Price Change, Percent	'	7.00%	'
Change in Fair Value of Call Option Feature	900,000	600,000	'
3.75% Convertible Notes	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Debt Instrument, Modified Debt, Unamortized Discount	'	'	$30,100,000

Debt_Outstanding_Convertible_D

Debt - Outstanding Convertible Debt and Related Deferred Financing Costs (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2011	Jun. 30, 2008	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2011	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified			5.375% Convertible Notes	5.375% Convertible Notes	3.75% Convertible Notes	3.75% Convertible Notes	3.75% Convertible Notes	2% Convertible Notes	2% Convertible Notes
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'
Principal amount of Senior Notes	'	'	'	$85,000	$28,836	$143,750	$143,800	$201,250	$0
Unamortized discount	-40,342	-30,099	-10,500	'	'	'	'	-35,600	'
Long-term Debt	189,744	113,651	'	'	'	'	'	'	'
Long-term debt	165,870	113,651	'	'	'	'	'	165,900	'
Current portion of long-term debt	23,874	0	'	'	'	'	'	'	'
Deferred financing costs	$5,638	$1,414	'	'	'	'	'	'	'

Debt_Interest_Expense_Detail

Debt - Interest Expense (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Debt Instrument [Line Items]	'	'	'	'
Contractual coupon interest	$1,273	$1,460	$2,621	$3,009
Accretion of debt discount	2,258	2,751	4,883	5,511
Amortization of debt issuance costs	192	149	338	297
Loss on extinguishment of debt	18,943	325	18,943	325
Interest and Other Expense, Total	$22,666	$4,685	$26,785	$9,142

Debt_Narrative_Detail

Debt - Narrative (Detail) (USD $)

1 Months Ended

3 Months Ended

6 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

1 Months Ended

Jun. 30, 2014

Jun. 30, 2013

31-May-13

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Jun. 30, 2011

Jun. 30, 2013

31-May-13

Jun. 30, 2011

Jun. 30, 2008

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2011

Jun. 30, 2011

Jun. 30, 2011

Jun. 30, 2014

Jun. 30, 2011

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Jun. 30, 2011

Jun. 30, 2011

Jun. 30, 2011

Jun. 30, 2011

Jun. 30, 2011

Jun. 30, 2011

Jun. 30, 2011

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Jul. 31, 2014

Jul. 31, 2014

Investor

5.375% Convertible Notes

5.375% Convertible Notes

5.375% Convertible Notes

5.375% Convertible Notes

5.375% Convertible Notes

5.375% Convertible Notes

5.375% Convertible Notes

5.375% Convertible Notes

5.375% Convertible Notes

5.375% Convertible Notes

5.375% Convertible Notes

3.75% Convertible Notes

3.75% Convertible Notes

3.75% Convertible Notes

3.75% Convertible Notes

3.75% Convertible Notes

3.75% Convertible Notes

3.75% Convertible Notes

3.75% Convertible Notes

3.75% Convertible Notes

3.75% Convertible Notes

3.75% Convertible Notes

3.75% Convertible Notes

3.75% Convertible Notes

3.75% Convertible Notes

2% Convertible Notes

2% Convertible Notes

2% Convertible Notes

2% Convertible Notes

2% Convertible Notes

2% Convertible Notes

Subsequent Event [Member]

Subsequent Event [Member]

Investor

Semi Annual Payment, First Payment

Semi Annual Payment, Second Payment

Investor

Debt discount related to premium payment in connection with the purchase

Debt discount related to the increase in the value of the conversion feature.

Modified Debt

New Debt

Semi Annual Payment, First Payment

Semi Annual Payment, Second Payment

Semi Annual Payment, First Payment

Semi Annual Payment, Second Payment

3.75% Convertible Notes

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Principal amount of Senior Notes

'

'

'

'

'

'

'

'

'

'

'

'

$85,000,000

'

'

'

'

$70,000,000

'

'

$28,836,000

$143,800,000

$28,836,000

'

$28,836,000

'

$143,750,000

'

'

'

'

'

'

'

$201,250,000

$201,250,000

$201,250,000

$0

'

'

'

'

Portion of 2% Notes purchased by 3.75% holders

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

98,200,000

'

'

'

'

'

'

'

Amount allocated to debt

112,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount allocated to equity

48,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loss on extinguishment of debt

'

'

'

18,943,000

325,000

18,943,000

325,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares Issued with debt conversion

'

26,523

620,122

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

348,535

'

Debt Instrument, Redemption, Principal Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

Interest Paid

'

'

'

'

'

'

'

'

'

'

300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt, interest rate

'

'

'

'

'

'

'

'

'

'

'

'

5.38%

'

'

'

'

'

'

'

'

3.75%

'

'

'

'

'

'

'

'

'

'

'

'

2.00%

2.00%

2.00%

'

'

'

'

'

Debt, maturity date

'

'

'

'

'

'

'

'

'

'

'

'

15-Jun-13

'

'

'

'

'

'

'

'

15-Jun-16

'

'

'

'

'

'

'

'

'

'

'

'

15-Jun-19

'

'

'

'

'

'

'

Debt Instrument, Repurchased Face Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

114,900,000

'

114,900,000

'

114,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Frequency of interest payment

'

'

'

'

'

'

'

'

'

'

'

'

'semi-annually

'

'

'

'

'

'

'

'

'semi-annually

'

'

'

'

'

'

'

'

'

'

'

'

'semi-annually

'

'

'

'

'

'

'

Debt Instrument Interest Rate Payment Day And Month

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'December 15

'June 15

'

'

'

'

'

'

'

'

'

'

'

'

'December 15

'June 15

'

'

'

'

'December 15

'June 15

'

'

Debt conversion rate

'

'

'

'

'

'

'

'

'

'

'

'

46.8467

'

'

'

'

'

'

'

'

38.1749

'

'

'

'

'

'

'

'

'

'

'

'

21.5019

'

'

'

'

'

'

'

Principal amount per note used in conversion rate

'

'

'

'

'

'

'

'

'

'

'

'

1,000

'

'

'

'

'

'

'

'

1,000

'

'

'

'

'

'

'

'

'

'

'

'

1,000

1,000

1,000

'

'

'

'

'

Other Asset - Call feature on the modified portion of the 3.75% Notes

702,000

'

'

702,000

'

702,000

'

1,351,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion price, per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$26.20

'

'

'

'

'

'

'

'

'

'

'

'

$46.51

$46.51

$46.51

'

'

'

'

'

Debt discount

40,342,000

'

'

40,342,000

'

40,342,000

'

30,099,000

'

'

'

10,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,100,000

200,000

25,800,000

26,600,000

'

'

35,600,000

35,600,000

35,600,000

'

'

'

'

'

Nonconvertible debt borrowing rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

16.50%

12.40%

'

'

6.20%

6.20%

6.20%

'

'

'

'

'

Debt discount amortization period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'5 years

'

'

'5 years

'

'

'

'

'

'

'

Finance costs reclassified against equity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

900,000

'

'

1,200,000

'

'

'

'

'

'

'

Deferred financing costs, amortization period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

Payments of long term debt

'

'

'

'

'

'

'

'

'

'

'

85,100,000

'

'

'

'

'

'

'

'

160,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument repurchase premium in dollars

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

45,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Principal Amount Of Old Debt Held

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

80,000,000

'

80,000,000

'

80,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Repurchase premium

'

'

'

'

'

'

'

'

'

'

'

21.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Principal Amount Of Modified Debt Held

'

'

'

'

'

'

'

'

73,000,000

'

'

'

'

'

'

'

'

13,500,000

'

'

'

'

'

'

'

'

'

59,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Prinicpal amount of debt converted

'

'

'

'

'

'

'

'

'

'

13,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Repayment of remaining prinicpal amount including interest

'

'

'

'

'

'

'

'

'

2,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

Interest expense related to Notes

'

'

'

'

'

'

'

'

'

'

'

'

'

0

100,000

0

300,000

'

'

'

'

'

1,100,000

1,400,000

2,400,000

2,700,000

'

'

'

'

'

'

'

'

'

200,000

200,000

'

'

'

'

'

Percentage required of the last reported sale price per share of the Company's common stock for redemption

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

130.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of trading days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'20 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of consecutive trading days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'30 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Principal amount of debt converted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

28,500,000

Transaction fees

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

'

'

'

Principal debt amount issued to new investors

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

84,300,000

'

'

'

'

'

'

'

'

'

'

Long-term debt

165,870,000

'

'

165,870,000

'

165,870,000

'

113,651,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

165,900,000

165,900,000

165,900,000

'

'

'

'

'

Non-cash interest and other expense

'

'

'

'

'

5,869,000

5,808,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,100,000

2,900,000

4,900,000

5,500,000

'

'

'

'

'

'

'

'

'

300,000

300,000

'

'

'

'

'

Current portion of long-term debt

23,874,000

'

'

23,874,000

'

23,874,000

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Discount, Unamortized

4,961,000

'

'

4,961,000

'

4,961,000

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred financing costs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2,800,000

'

'

$6,700,000

$6,700,000

$6,700,000

'

'

'

'

'

Capital_Lease_Obligations_Sche

Capital Lease Obligations - Schedule of Capital Leased Assets (Details) (Machinery and Equipment [Member], USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Machinery and Equipment [Member]	'	'
Capital Leased Assets [Line Items]	'	'
Manufacturing Equipment	$6,510	$6,510
Less: Accumulated Depreciation	-1,233	-582
Total	$5,277	$5,928

Capital_Lease_Obligations_Sche1

Capital Lease Obligations - Schedule of Future Minimum Lease Payments for Capital Leases (Details) (USD $)	Jun. 30, 2014
In Thousands, unless otherwise specified
Leases, Capital [Abstract]	'
2014 (remaining)	$1,907
2015	3,815
2016	2,409
Total future minimum lease payments	8,131
Interest Expense	-1,366
Total capital lease obligations	$6,765

Capital_Lease_Obligations_Addi

Capital Lease Obligations - Additional information (Details) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Capital Leased Assets [Line Items]	'	'	'	'	'
Interest Expense	$300,000	$0	$600,000	$0	'
Repayment Period for Capital Lease Obligations	'	'	'	'	'36 months
Capital Leases of Lessee, Contingent Rentals, Effective Interest Rate	'	'	'	'	17.00%
Machinery and Equipment [Member]	'	'	'	'	'
Capital Leased Assets [Line Items]	'	'	'	'	'
Capital Lease Assets prior to write down	'	'	'	'	9,000,000
Asset Impairment Charges	'	'	'	'	2,500,000
Manufacturing Equipment	6,510,000	'	6,510,000	'	6,510,000
Property, Plant and Equipment, Useful Life	'	'	'	'	'5 years
Amortization Expense	$400,000	$0	$700,000	$0	'

Net_Loss_Per_Share_Potential_C

Net Loss Per Share - Potential Common Shares Excluded from Computation of Diluted Net Loss Per Share (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share, amount	8,030,735	9,594,181	8,030,735	9,594,181
5.375% Convertible Notes	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share, amount	0	702,701	0	702,701
3.75% Convertible Notes	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share, amount	1,100,811	5,487,642	1,100,811	5,487,642
2% Convertible Notes	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share, amount	4,327,257	0	4,327,257	0
Restricted Stock Units	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share, amount	968,083	1,058,032	968,083	1,058,032
Outstanding options	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share, amount	1,634,584	2,283,054	1,634,584	2,283,054
Outstanding warrants	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share, amount	0	62,752	0	62,752

Accounts_Receivable_Components

Accounts Receivable - Components of Accounts Receivable (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Receivables [Abstract]	'	'
Trade receivables	$48,542	$40,200
Allowance for doubtful accounts	-6,745	-7,133
Accounts receivable, net	$41,797	$33,067

Accounts_Receivable_Narrative_

Accounts Receivable Narrative (Details)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
	customer	customer
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Number Of Customers With Greater Than Ten Percent Accounts Receivable Balance	2	2
Concentration Risk, Percentage	29.00%	36.00%
Customer One	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Concentration Risk, Percentage	16.00%	12.00%
Customer Two	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Concentration Risk, Percentage	15.00%	10.00%

Inventories_Components_of_Inve

Inventories - Components of Inventories (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Schedule of Inventory [Line Items]	'	'
Raw materials	$917	$399
Work-in-process	856	1,671
Finished goods	6,992	7,394
Total inventories	$8,765	$9,464

Other_Intangible_Assets_Compon

Other Intangible Assets - Components of Other Intangible Assets (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Acquired Finite-Lived Intangible Assets [Line Items]	'	'
Other intangible assets cost	$32,900	$32,900
Less: Accumulated amortization	-17,018	-14,860
Total	15,882	18,040
Customer Relationships [Member]	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'
Other intangible assets cost	30,100	30,100
Less: Accumulated amortization	-16,443	-14,378
Total	13,657	15,722
Tradename [Member]	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'
Other intangible assets cost	2,800	2,800
Less: Accumulated amortization	-575	-482
Total	$2,225	$2,318

Other_Intangible_Assets_Amorti

Other Intangible Assets Amortization Expense Expected for Next Five Years (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Expected Amortization Expense [Line Items]	'	'
2014 (remaining)	$1,819	'
2015	3,251	'
2016	2,665	'
2017	2,190	'
2018	1,806	'
Thereafter	4,151	'
Total	15,882	18,040
Customer Relationships [Member]	'	'
Expected Amortization Expense [Line Items]	'	'
2014 (remaining)	1,725	'
2015	3,064	'
2016	2,478	'
2017	2,003	'
2018	1,619	'
Thereafter	2,768	'
Total	13,657	15,722
Tradename [Member]	'	'
Expected Amortization Expense [Line Items]	'	'
2014 (remaining)	94	'
2015	187	'
2016	187	'
2017	187	'
2018	187	'
Thereafter	1,383	'
Total	$2,225	$2,318

Other_Intangible_Assets_Narrat

Other Intangible Assets - Narrative (Detail) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2011	Dec. 31, 2013
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'	'
Other intangible assets cost	'	'	'	'	$32,900,000	'
Accumulated amortization	17,018,000	'	17,018,000	'	'	14,860,000
Amortization of other intangible assets	1,100,000	1,300,000	2,200,000	2,700,000	'	'
Intangible asset, weighted average amortization period	'	'	'8 years	'	'	'
Intangible assets	15,882,000	'	15,882,000	'	'	18,040,000
Customer Relationships [Member]	'	'	'	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'	'
Estimated useful life	'	'	'	'	'10 years	'
Accumulated amortization	16,443,000	'	16,443,000	'	'	14,378,000
Intangible assets	13,657,000	'	13,657,000	'	'	15,722,000
Tradename [Member]	'	'	'	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'	'
Estimated useful life	'	'	'	'	'15 years	'
Accumulated amortization	575,000	'	575,000	'	'	482,000
Intangible assets	$2,225,000	'	$2,225,000	'	'	$2,318,000

Product_Warranty_Costs_Narrati

Product Warranty Costs - Narrative (Detail)	6 Months Ended
	Jun. 30, 2014
Schedule of Accrued Liabilities [Line Items]	'
Product warranty term for PDMs	'4 years

Product_Warranty_Costs_Reconci

Product Warranty Costs - Reconciliation of Changes in Product Warranty Liability (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Movement in Standard and Extended Product Warranty, Increase (Decrease) [Roll Forward]	'	'	'	'
Balance at the beginning of the period	$3,100	$2,249	$3,090	$1,992
Warranty expense	-150	785	542	1,661
Warranty claims settled	-445	-633	-1,127	-1,252
Balance at the end of the period	$2,505	$2,401	$2,505	$2,401

Product_Warranty_Costs_Product

Product Warranty Costs - Product Warranty Liability (Detail) (USD $)	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Composition of balance:	'	'	'	'	'	'
Short-term	$994	'	$1,173	'	'	'
Long-term	1,511	'	1,917	'	'	'
Total warranty balance	$2,505	$3,100	$3,090	$2,401	$2,249	$1,992

Commitments_and_Contingencies_1

Commitments and Contingencies - Operating Leases (Detail)	6 Months Ended							6 Months Ended
	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014	Jun. 30, 2013
	Bedford, Massachusetts	Woburn, Massachusetts	Singapore	FLORIDA	New York State	Billerica Massachusetts, New Location [Member]	Billerica Massachusetts, New Location [Member]	Billerica Massachusetts, New Location - Warehouse [Member]	Billerica Massachusetts, New Location - Warehouse [Member]
							sqft		sqft
Operating Leased Assets [Line Items]	'	'	'	'	'	'	'	'	'
Area of Real Estate Property	'	'	'	'	'	'	90,000	'	18,000
Lease expiration date	'2014-09	'2014-12	'2015-07	'2014-12	'2015-04	'2022-10	'	'2019-09	'

Commitments_and_Contingencies_2

Commitments and Contingencies - Legal Proceedings (Details) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014
Loss Contingencies [Line Items]	'
Litigation Settlement, Expense	$7
Patents | Becton Dickinson and Company	'
Loss Contingencies [Line Items]	'
Number Of Patents Allegedly Infringed On	2

Commitments_and_Contingencies_3

Commitments and Contingencies - Aggregate Future Minimum Lease Payments (Detail) (USD $)	Jun. 30, 2014
In Thousands, unless otherwise specified
Minimum Lease Payments	'
2014 (remaining)	$776
2015	2,096
2016	2,057
2017	2,139
2018	2,144
Thereafter	8,249
Total	$17,461

Equity_Additional_Information_

Equity - Additional Information (Detail) (USD $)

1 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

1 Months Ended

1 Months Ended

Jun. 30, 2013

31-May-13

Jan. 31, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2013

31-May-13

Jan. 31, 2013

31-May-13

Jan. 31, 2013

Nov. 30, 2013

Employee Stock Option

Employee Stock Option

Employee Stock Option

Employee Stock Option

5.375% Convertible Notes

5.375% Convertible Notes

Additional Paid-in Capital [Member]

Common Stock [Member]

Common Stock [Member]

Warrant [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options outstanding, shares

'

'

'

1,634,584

'

1,634,584

'

1,828,613

'

'

'

'

'

'

'

'

'

'

Shares of common stock issued and sold

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

620,122

4,715,000

'

Common stock price per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$20.75

'

Proceeds from Issuance of Common Stock

'

'

$97,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds of Issuance of Common Stock Net of Expenses

'

'

'

'

'

'

'

'

'

'

'

'

'

'

92,800,000

'

'

'

Shares Issued with debt conversion

26,523

620,122

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Other

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

47,392

Prinicpal amount of debt converted

'

'

'

'

'

'

'

'

'

'

'

'

'

13,000,000

'

'

'

'

Repayment of remaining principal of 5.375% Notes

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

'

'

Stock-based compensation expense

'

'

'

4,200,000

3,800,000

8,600,000

6,800,000

'

1,300,000

1,300,000

2,900,000

2,500,000

'

'

'

'

'

'

Total unrecognized compensation expense

'

'

'

$36,500,000

'

$36,500,000

'

'

$10,700,000

'

$10,700,000

'

'

'

'

'

'

'

Equity_Stock_Option_Activity_D

Equity - Stock Option Activity (Detail) (USD $)	6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014
Number of Options	'
Beginning balance (in shares)	1,828,613
Granted (in shares)	227,500
Exercised (in shares)	-403,371
Canceled (in shares)	-18,158
Ending balance (in shares)	1,634,584
Vested, at end of period (in shares)	923,061
Vested and expected to vest, at end of period (in shares)	1,370,909	[1]
Weighted Average Exercise Price	'
Beginning balance (in USD per share)	$16.46
Granted (in USD per share)	$42.67
Exercised (in USD per share)	$12.70
Canceled (in USD per share)	$23.09
Ending balance (in USD per share)	$20.97
Vested, at end of period (in USD per share)	$15.27
Aggregate Intrinsic Value	'
Exercised	$11,615	[2]
Ending balance	31,509
Vested, at end of period	22,523	[3]
Vested and expected to vest, at end of period	$27,826	[3]
Estimated forfeiture rate	16.00%
[1]	Represents the number of vested options as of June 30, 2014, plus the number of unvested options expected to vest as of June 30, 2014, based on the unvested options outstanding as of June 30, 2014, adjusted for the estimated forfeiture rate of 16%.
[2]	The aggregate intrinsic value was calculated based on the positive difference between the fair market value of the Company’s common stock as of the date of exercise and the exercise price of the underlying options.
[3]	The aggregate intrinsic value was calculated based on the positive difference between the fair market value of the Company’s common stock as of June 30, 2014 and the exercise price of the underlying options.

Equity_Stock_Options_Narrative

Equity - Stock Options Narrative (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Options outstanding, shares	1,634,584	'	1,634,584	'	1,828,613
Options outstanding, weighted average exercise price	$20.97	'	$20.97	'	$16.46
Options outstanding, weighted average remaining contractual life	'	'	'7 years 0 months 0 days	'	'
Options exercisable, shares	923,061	'	923,061	'	'
Options exercisable, weighted average exercise price	$15.27	'	$15.27	'	'
Options exercisable, weighted average remaining contractual life	'	'	'5 years 8 months 15 days	'	'
Stock-based compensation expense	$4,200,000	$3,800,000	$8,600,000	$6,800,000	'
Total unrecognized compensation expense	36,500,000	'	36,500,000	'	'
Shares available for future issuance	2,544,999	'	2,544,999	'	'
Employee Stock Purchase Plans	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Stock-based compensation expense	0	0	0	0	'
Stock Issued During Period, Shares, Employee Stock Purchase Plans	'	'	6,898	6,390	'
Employee Stock Option	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Stock-based compensation expense	1,300,000	1,300,000	2,900,000	2,500,000	'
Total unrecognized compensation expense	$10,700,000	'	$10,700,000	'	'
Total unrecognized compensation expense weighted-average period	'	'	'1 year 3 months 18 days	'	'

Equity_Employee_Stock_Purchase

Equity - Employee Stock Purchase Plan Narrative (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation expense	$4,200,000	$3,800,000	$8,600,000	$6,800,000
Employee Stock Purchase Plans	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation expense	$0	$0	$0	$0
Shares contingently issued under employee stock purchase plan	'	'	6,898	6,390

Equity_Restricted_Stock_Units_

Equity - Restricted Stock Units Narrative (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation expense	$4,200,000	$3,800,000	$8,600,000	$6,800,000
Total unrecognized compensation expense	36,500,000	'	36,500,000	'
Restricted Stock Units	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Shares granted during the period	'	'	321,375	'
Other than options - granted in period, weighted average fair value	'	'	$45.51	'
Other than options - grant date fair value	'	'	14,600,000	'
Stock-based compensation expense	2,900,000	2,500,000	5,700,000	4,300,000
Total unrecognized compensation expense	25,800,000	'	25,800,000	'
Total unrecognized compensation expense weighted-average period	'	'	'1 year 6 months 15 days	'
Restricted Stock Units | Minimum	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Vesting period	'	'	'3 years	'
Restricted Stock Units | Maximum	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Vesting period	'	'	'4 years	'
Performance Shares	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Shares granted during the period	'	'	34,500	'
Performance Shares | Minimum	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Vesting period	'	'	'3 years	'
Employee Stock Option	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation expense	1,300,000	1,300,000	2,900,000	2,500,000
Total unrecognized compensation expense	$10,700,000	'	$10,700,000	'
Total unrecognized compensation expense weighted-average period	'	'	'1 year 3 months 18 days	'

Equity_Summary_of_Restricted_S

Equity - Summary of Restricted Stock Units (Detail) (USD $)	6 Months Ended
	Jun. 30, 2014
Restricted Stock Units	'
Number of Shares	'
Beginning balance (in shares)	1,011,893
Granted (in shares)	321,375
Vested (in shares)	-342,990
Forfeited (in shares)	-22,195
Ending balance (in shares)	968,083
Weighted Average Fair Value	'
Beginning balance (in USD per share)	$22.11
Granted (in USD per share)	$45.51
Vested (in USD per share)	$21.10
Forfeited (in USD per share)	$21.46
Ending balance (in USD per share)	$30.25
Performance Shares	'
Number of Shares	'
Granted (in shares)	34,500
Minimum | Restricted Stock Units	'
Number of Shares	'
Vesting period	'3 years
Minimum | Performance Shares	'
Number of Shares	'
Vesting period	'3 years

Income_Taxes_Income_Tax_Expens

Income Taxes - Income Tax Expense (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income Tax Expenses [Line Items]	'	'	'	'
Current	$22	$88	$53	$191
Deferred	30	30	64	58
Total	$52	$118	$117	$249

Income_Taxes_Narrative_Detail

Income Taxes - Narrative (Detail) (USD $)	Jun. 30, 2014
In Millions, unless otherwise specified
Disclosure Income Taxes Additional Information [Abstract]	'
Unrecognized Tax Benefits	$0